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Abstract 
New research into the medicinal properties of compounds within Cannabis is changing the 
way this convert plant material is used, both in Western Australia and around the world. The 
abuse of Cannabis as an illicit and recreational drug has been the focus of research for many 
decades, however this focus is shifting towards potential therapeutic benefits, such as pain 
relief and anti-seizure applications. Cannabis contains many compounds of pharmacological 
relevance, but the group of most interest is the cannabinoids. These include the main 
psychoactive component of Cannabis, Δ9tetrahydrocannabinol (THC), which is the focus of 
legislation in Australia, with regulation for manufacture of hemp materials restricting content 
to less than 0.3% w/w. There are numerous other cannabinoids that may be of benefit for 
medicinal applications, as they appear not to exhibit the negative psychoactive effects of 
THC. In order for them to be better understood and developed, new analytical techniques are 
needed to identify and quantify these other cannabinoids. 
The aim of this study was to utilise current instrumentation to develop and optimise a method 
to separate and quantify 11 common cannabinoids. The target cannabinoids were: Δ8 and 
Δ9THC, cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene 
(CBC), cannabidivarin (CBDV), tetrahydrocannabivarin (THCV, cannabigerolic acid 
(CBGA), cannabidiolic acid (CBDA) and Δ9tetrahydrocannabinolic acid A (THCA-A). The 
three instrumental techniques explored were gas chromatography/mass spectrometry 
(GC/MS), liquid chromatography/photodiode array (LC/PDA) and liquid 
chromatography/tandem mass spectrometry (LC/MS/MS). 
GC/MS is well-established for both cannabinoid analysis and Δ9THC quantification. The 
method optimised in this study utilized previous work, with a focus on neutral cannabinoids. 
After optimisation of ramp rates and columns for GC/MS, 8 neutral cannabinoids were 
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separated and quantified. Peak signals and retention times varied between analyses, meaning 
that identification was challenging.  
LC/PDA provided some advantages to GC/MS, as the cannabinoids were more stable using 
this ‘softer’ technique. LC/PDA method optimisation focused on flow rate, buffers and 
gradients, with all 11 cannabinoids separated and quantified. Retention times variability was 
observed, but this was found to be due to instrumental problems. The key disadvantage of 
this method was the inability to discriminate between cannabinoids based solely on their UV 
spectra. Oil and plant material samples were successfully analysed via this method and found 
to contain a range of cannabinoids at various concentrations. The data was compared with 
previous methods and found to be equivalent or better. Full validation of the LC/PDA method 
could not be completed, but data to date is promising. 
LC/MS/MS was able to individually detect and identify several cannabinoids, with 7 peaks 
observed in the mixed standard. This demonstrated issues with co-elution, in addition to 
higher noise levels for this method. LC/MS/MS combined the best of both GC/MS and 
LC/PDA, using a ‘softer’ chromatographic technique (LC) with a detection method with 
greater discriminatory power (MS).  
The ability to separate and analyse all 11 cannabinoids simultaneously would be an 
advantage to the medicinal Cannabis industry, as a commercial method that has high 
throughput, and is time and material efficient would provide essential information on 
composition of products. It would also allow us to identify products that may produce a 
desired or undesired therapeutic effect. Additionally, this research aids monitoring of the 
products for legislative purposes. When fully developed and optimised, the method could be 
implemented in a commercial setting to quantify cannabinoids in Cannabis and Cannabis 
products such as oils. 





Δ9THCA-A Delta-9-tetrahydrocannabinolic acid A 
Δ9THCA-B Delta-9-tetrahydrocannabinolic acid B 
CBC Cannabichromene 
CBCA Cannabichromenic acid 
CBD Cannabidiol 
CBDA Cannabidiolic acid 
CBDV Cannabidivarin 
CBG Cannabigerol 
CBGA Cannabigerolic acid 
CBN Cannabinol 
CBNA Cannabinolic acid 
DNA Deoxyribonucleic acid 
D3-Δ
9THC Deuterated delta-9-tetrahydrocannabinol 
EI Electron ionization 
ESI Electrospray ionization 
FID Flame ionization detector 
GC Gas chromatography 
GC/MS Gas chromatography/mass spectrometry 
HPLC High performance liquid chromatography 
LC Liquid chromatography 
LC/MS/MS Liquid chromatography/ tandem mass spectrometry 
LC/PDA Liquid chromatography/ photodiode array 
LoD Limit of detection 
LoQ Limit of quantification 
MS Mass spectrometry 
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MS/MS Tandem mass spectrometry 
NATA National Association of testing authorities 
NZ New Zealand 
PDA Photodiode array 
RSD Relative standard deviation 
SD Standard deviation 
SPE Solid phase extraction 
THCV Tetrahydrocannabivarin 
TLC Thin layer chromatography 
UHPLC Ultra-high-performance liquid chromatography 
UHPSFC/PDA-MS Ultra-High-Performance Supercritical Fluid Chromatography and 
Photodiode Array/Mass Spectrometric Detection 
UPLC Ultra-performance liquid chromatography 
USA United States of America 
UV Ultra violet 
WA Western Australia 
WAPOL Western Australia Police 
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CHAPTER 1: Literature Review 
1.1 Cannabis 
The Cannabis plant has a characteristic star-like shape and serrated leaves (Figure 1.1) and 
trichomes1-5 (Figure 1.2). Cannabis has a multitude of uses including as a fibre, a 
psychotropic drug and more recently a medicine2,6-9. Most notably is the drug form of 
Cannabis also known as marijuana, pot or grass5, this form is usually smoked via pipes or 
cigarettes to produce a euphoric effect2,5. The drug form of Cannabis is illicit in Australia10-12 
and its use is estimated at about 35% in Australians aged over 1413-15 with approximately 
16% using it consistently13-15. This may be a reflection of modern society as this level of 
Cannabis use has been consistent for many decades8,9.  The analysis of Cannabis and its 
components has been a topic of focus for scientists in a multitude of research areas for 
decades, given its multiple functions both medicinally and industrially, such as in clothes, 
food, paper and biofuel1,2,16 to name a few. Therapeutic uses are entering mainstream 
medicine, with the pharmacological properties of certain Cannabis compounds on the human 
body being increasingly studied and advocated for by the public8,9,16. Tetrahydrocannabinol 







Figure 1.2: Glandular trichomes of Cannabis5 
 
Figure 1.1: Photo of Cannabis leaves5 
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The composition of Cannabis is a principal factor in the use of the plant for multiple purposes 
such as medicine. Cannabis has become increasingly valuable and to have the commercial 
ability in Australia to identify the compounds of which it consists inclusive of their 
structures, uses, pharmacological and physiological effects would be advantageous in the 
future.  Cannabis has been researched and instrumentally and chemically profiled for over 50 
years16,24. To date over 700 compounds have been identified3,7,20-22, including terpenoids, 
flavonoids, nitrogenous compounds and cannabinoids3. Cannabinoids are the psychoactive 
compounds within the Cannabis plant; THC is a cannabinoid along with many other similarly 
structured compounds which act on the cannabinoid receptor in the human brain25-28. 
Cannabinoids are the components of interest for this study with approximately 70 known 
cannabinoids identified to date6,7,20,29. Many of the 70 cannabinoids are scarce in the literature 
and compared to THC detected in low quantities in raw samples; with approximately 10-15 
cannabinoids routinely quantified via instrumental techniques. More cannabinoids can be 
identified currently by GC/MS than can be quantified by LC/PDA. 
Recently, the changes in the legislated use of Cannabis has engendered the need to determine 
the THC content in plant samples1,12,30-33. Australian legislation defined the composition of 
THC in raw plant material so that a binary classification could be produced: licit and 
illicit11,31,32. Further government inquiry has arisen due to the prevalence and popularity of 
Cannabis medicines, and the related importance of the other cannabinoids, blurring the 
binary system previously used14,30,33.  The ability to identify and quantify each cannabinoid in 
different Cannabis products and/or strains has therefore becoming more relevant in this 
decade. Liquid and gas chromatography have been the main separation techniques for the 
analysis of cannabinoids, but to date quantification of multiple cannabinoids in Cannabis and 
derived products is still in development in WA. 
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1.1.1 Cannabis species 
Cannabis sativa is the species most commonly examined in analytical and medicinal 
research, this is due to this species being the most commonly grown in Australia and around 
the world2. It has a very identifiable botanical morphology, and as a dioecious plant, the male 
and female reproductive organs are found on separate individuals1-5,34. The female plants 
contain the flowering heads which contain the highest concentration of THC making them the 
most sought after for illicit activities, additionally their trichomes (unicellular hairs) produce 
larger amounts of resin than their male counterparts1-5,34,35. Cannabis resin is the term for the 
liquid-like formation that is present on the trichomes of the plant, this resin contains the 
cannabinoids and is extracted to make Cannabis oils and butters1-5,30,31. The species believed 
to exist are as follows: Cannabis. Sativa (C. sativa), C. indica, C. ruderalis, C. chinensis and 
C. inflorescences2,5,36,37. However, there are believed to be over 100 different morphological 
variants of Cannabis available today24,36, thought to be caused by selection to accommodate 
growth under different conditions for varying purposes, or due to restraints on the grower 
such as limited outdoor space or the need to hide illicit growing. Some variants have likely 
come about due to the use of hemp for food and clothing1, through genetic modification35,37 
and illicit growing using indoor hydroponic setups5,18. The use of morphology alone is not 
sufficient to discriminate between different types of Cannabis.  
The ability to discriminate Cannabis types would be beneficial for law enforcement, growers, 
medicinal users and manufacturers of Cannabis products. Methods that enable this 
discrimination would be beneficial and aid the above industries in furthering their services 
and knowledge on the products seized or produced. Chemical composition-based 
characterisation tools or genetic profiling38 are some definitive ways to distinguish Cannabis 
types for research and legislative purposes. Genetic profiling uses sections of the 
deoxyribonucleic acid (DNA) sequence Cannabis to identify differences and then attempts to 
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relate these differences to a function or characteristic of a certain type of Cannabis38,39. 
Chemical composition based methods would utilise more chemical techniques, an approach 
that could be used is a characterisation system, a system such as this currently used is by 
chemotypes17,24,31,38-41. Cannabis chemotypes are defined via their ratio of THC content to 
cannabidiol (CBD) which are the most abundant and well-known cannabinoids. 
There are three different chemotypes defined by THC/CBD content, this is sometimes 
calculated as [THC + Cannabinol (CBN)]/CBD5,40,41. Chemotype I is commonly referred to 
as the drug type, with its very high THC content producing a THC/CBD ratio significantly 
greater than 1, which typically contains THC at approximately 3.0% w/w5,21,40,41. Chemotype 
II is termed the intermediate type and is defined by its intermediate ratio around 1 which 
typically ranges from 0.5 to 3.0% THC w/w5,21,40,41. The fibre or non-drug type which is 
defined by its very low THC content, less than 0.3% w/w and a ratio of significantly less than 
15,21,40,41 is described as chemotype III. Hemp is characterised as chemotype III and has been 
bred to contain this low THC modification. It is characterised as the legal type in the binary 
classification, with samples containing above 0.3% THC defined as illicit5,21,24,41.  
1.1.2 Cannabinoids 
Cannabinoids are a group of chemical compounds found only in Cannabis2,16,29,42. The group 
of compounds are structurally similar, some cannabinoids are precursors for others with some 
cannabinoids being naturally synthesised biologically from other cannabinoids initially 
present in the plant material21,22. Cannabinoid production is also achieved via the 
decomposition of a precursor cannabinoid by plant enzymes or other natural forces, such as 
heat or air21,22, to produce compounds with different properties. Cannabigerolic acid (CBGA) 
is the primary precursor for many of the cannabinoids15,16. From CBGA, four cannabinoids 
are immediate products (Figure 1.3)22, with one, cannabigerol (CBG) synthesised via 
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decarboxylation16 and three produced via various acid synthase enzymes: 
tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA) and cannabichromenic acid 













Older or decomposed plants commonly undergo further reactions in the presence of air and/or 
light20-22,29,35, resulting in more cannabinolic acid or cannabinol (CBNA or CBN) being 
present than THC/THCA5,22,29,40. This knowledge may inform sample extraction, as the 
composition of the extracted cannabinoids will change depending on the age of the plant 
when extracted5,21,35,38,43,44. Similarly, the heating of the plant, which is often observed when 
consumption is by way of smoking, will alter the chemical structure of the 
Figure 1.3: DeBacker et al. 200922 biosynthetic pathways in Cannabis  
 
-  6  -  |  P a g e  
 
cannabinoids6,16,17,21,42. As above, THCA/THC often breaks down to CBNA/CBN5,20,22,29,40,43, 
but the predominant effect of heating is the decarboxylation of all cannabinoids5,20-22,29,43 
present in the plant material. This function alters the natural acidic state of the compounds to 
a neutral form5,20-22,29,35, which is the most observed form due to the techniques used to 
analyse Cannabis.  
1.1.2.1 Tetrahydrocannabinol 
It was isolated and discovered in 196423. It is the psychoactive component of Cannabis and 
the compound responsible for the well-known effects of the chemotype I material16,17,19,21-
23,45. In the unaltered plant material, THC exists in its acid form, tetrahydrocannabinolic acid 
(THCA)22,43, thus the acidic form is the most abundant cannabinoid in the natural plant 
material. THCA is not psychoactive and exists in two isomeric forms, THCA-A and THCA-
B15,16,30. The most abundant of the two acid forms is the A structure which places the 
carboxyl group at position two22,46,47, while structure B has the carboxyl group at position 
six46-48 (Figure 1.4). THCA in this study refers to the A isomer only, as THCA-B is rarely 
encountered, as its structure is less stable46,47. Both acidic isomers are decarboxylated on 






Figure 1.4: Structural conformations of THCA-A and THCA-B47 
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The THC produced by decarboxylation (generally by artificial heating or light) is commonly 
found in delta-9 (Δ9THC) (Figure 1.5) isomeric configuration6,22,37,43, this is the most 
abundant and active form referred to in literature. Delta-8-tetrahydrocannabinol (Δ8THC) 
(Figure 1.5) is less predominant but still well researched. It is less potent and exhibits few of 
the psychoactive traits of the Δ9 isomer15,16,27, making it a prime candidate for medical 
research21,22,37. THC in legislation and articles usually refers to Δ9THC unless otherwise 






1.1.3 Medicinal Cannabis and the future 
Across the world, medicinal oils, balms2,8,9,29,49 and genetically modified strains35,37 have 
been produced to aid the treatment of different illnesses8,9,16,27,45,49. The therapeutic properties 
of the two central cannabinoids, THC and CBD, have been widely researched and 
documented7,16,25,27,35,50 (Table 1.1), with some contrasting conclusions in regards to 
mechanisms of action, ideal intake methods and single or multi-component products16,37. 
Recent Australian legislation for medicinal Cannabis is fast tracking the need to identify the 
types and quantities of cannabinoids in a specific product. A priority is to determine whether 
the correct and intended compounds are present and if these products can be identified as a 
legal chemotype, the current legal chemotype is III which contains less than 0.3%w/w THC. 
The illicit variety of Cannabis is quite prevalent in Australian communities13-15, this is what 
9 
8 
Δ8THC 9 Δ9THC 
8 
Figure 1.5: Structural diagrams of Δ8 and Δ9 THC. 
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creates a possible problem with legalised growing, extraction and modification of Cannabis 
as a distinction between the illicit and legal materials must be made. 
The manufacturing process of Cannabis based medicines produces a unique challenge in 
terms of modern pharmacology. Modern pharmacology uses the principle that a prescribed 
dose will produce an expected effect15,24,37,51. This is the case for some pharmaceutical 
products containing known amounts of one or two cannabinoids, usually THC and CBD, 
where a single compound has a single target15,24,29,37,45. An example of a product such as this 
is Sativex © or Marinol © 7,16. 
The single target single compound method is not always the case for medicinal grade 
Cannabis and derived products where the composition of the product is largely unknown and 
the dose prescribed is often based on observation or patient accounts2,7,37,49,52. The therapeutic 
index of these medicinal products is yet to be defined to an appropriate level2,37, in order to 
limit toxicity. The concentration of cannabinoids in product manufactured from medicinally 
bred Cannabis may be unknown due to the difficulties in manufacturing specific 
compositions in the precursor plant material, this makes a prescribed dose difficult to 
determine. Without known concentrations in medicines a dose effect relationship cannot be 
created to eliminate this ‘trial and error’ method on patients. 
Due to breeding processes, it is possible that some medicinal products contain higher levels 
of THC than intended. Popular products in the United States of America such as Sativex and 
Marinol utilise cannabinoid properties from compounds that are naturally derived or 
synthesised respectively7,16. These products attempt to mimic the properties of the natural 
compounds7,10. The therapeutic properties of cannabinoids are reputable2,7,27, however they 
need to be regulated as they are deemed illegal and display detrimental properties at high 
intake levels such as: increased heart rate, paranoia, short-term memory loss and drastic 
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mood swings37. Trials of Cannabis products in New South Wales began in 2014 on 
terminally ill patients, the results so far are promising26,53. Further identification requirements 
into the composition of the products has prompted the need for the analysis of naturally 
derived Cannabis products in Australia to determine content and therefore possible dose. 
Many papers and books on the structures and properties of select cannabinoids have been 
published2,6,23, this research provided the foundation for the extraction and modification of 
specific cannabinoids to produce easily consumable or absorbable medicines. The believed 
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Table 1.1: The associated activity of select cannabinoids7,16,25,27,35,50. 







Relieves vomiting and nausea 
Aids sleep 
THCA Aids sleep 
Inhibits cancer cell growth 
Supresses muscle spasms 
Δ8THC Pain relief 
CBD Antibacterial 
Inhibit cancer cell growth 




Relieves vomiting and nausea 
CBDA Reduces inflammation 
Inhibits cancer cell growth 
CBG Aids sleep 
Inhibits cancer cell growth 
Promotes bone growth 
Slows bacterial growth 
CBGA Reduces inflammation 
Relieves pain 
Slows bacterial growth 
CBC Inhibits cancer cell growth 
Promotes bone growth 
Reduces inflammation 
Relieves pain 
THCV Reduces convulsion and seizures 
Promotes bone growth 
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1.1.3.1 Synergistic effects between cannabinoids and other Cannabis compounds 
Different combinations of cannabinoids have been researched to observe any additive effects 
with both medicinal and recreational use45,49,54. There is a consensus that without Δ9THC, the 
other cannabinoids may aid in the treatment of many illnesses or pain relief without 
psychoactive effects2,18,37,49. However, cumulative theories known as the ‘entourage effect’ 
suggest a more synergistic method of treatment that use whole plant rather than isolated 
compound medicines45,49,54.  
Due to the wide variety of compounds present in Cannabis, there are different compounds 
present in Cannabis extracts, such as the terpenes, that may exert regulatory effects on the 
more active components45,54. That is, the non-cannabinoid components may be responsible 
for the uptake of cannabinoids by the brain2, and the biological activity in the patient may be 
altered by binding promotion or blocking at different receptors31,42, thus the concentration of 
these compounds may also be crucial for intended dosage and treatments. The amount and 
type of cannabinoids and non-cannabinoids present can be genetically altered or selected via 
extraction (when and how) and post-extraction techniques2,37, this is the focus of current 
medicinal research. 
1.1.4 Legislation and Quality 
Regulations surround the monitoring of Cannabis and THC. In Australia, the Industrial Hemp 
Act 200431 was introduced which explains the requirements to legally grow and distribute 
chemotype III crops. The legal status of medicinal Cannabis was amended in the Narcotic 
Drugs Regulation 201612. This amendment legalised the prescription of Cannabis medicines 
by doctors. This legalisation has prompted the requirement to quantitate and profile the 
constituents of the medicinal crops and medication products11,31,55.  
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Regulatory bodies dictate the standards for hemp and Cannabis medicines regarding THC 
content; the Australia and New Zealand hemp regulations 201056, the Regulator of Medicinal 
Cannabis Bill 201433 and a draft Public Health (Medicinal Cannabis) Bill 201630. There are 
quality guidelines around the production of these products and for their analysis. Analytical 
laboratories typically follow the recommended methods published by the United Nations 
Office on Drugs and Crime5, while also meeting an in-house or national quality standard. 
Reputable Australian forensic laboratories adhere to national quality standards produced by 
the National Association of Testing Authorities (NATA) which ensure analytical methods 
adhere to a defined standard in aspects such as calibration acceptability, repeatability and 
reliability of the methods. This level of validation is a goal for this research. However, most 
regulatory bodies and legislation refer to THC only, as the presence of high levels of this is 
what could make a product illicit. 
1.2 Sample Preparation and Analysis of Cannabis sample types 
The form of Cannabis analysed can influence research and possible outcomes of any 
experiment. Plant material is the most commonly used sample for research and manufacture 
of medicinal products. It is the rawest and most abundant form with the added ease of access, 
meaning that this is the form with the most accumulated data. This provides a basis for 
further analysis due to the number of compounds contained in the primary material. The need 
for methods that can analyse other, less common sample types is now becoming more 
relevant due to the surge in medicinal products utilising Cannabis-derived compounds. 
Research into Cannabis seed and seedling analysis has been undertaken to determine 
chemotypes before crop growth21,40,57. Seeds exhibited much lower cannabinoid contents than 
the plant material5,21,40,57, demonstrating the need for a technique to extract and detect lower 
quantities. To date, quantitation techniques are generally inadequate for low concentrations 
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such as those in seeds or seedling5,21,40,57.  Similarly, Cannabis oils, resins and balms 
produced by pharmaceutical companies also contain relatively low amounts of 
cannabinoids16. Quantifying cannabinoids in available or future medicines is a task that needs 
further attention.  
More obscure Cannabis products such as edibles (butter, baked goods, etc.) and genetically 
modified crops also need investigation. Each of these forms holds unique cannabinoids at 
concentrations which present challenges in terms of a defined calibration range, instrument 
sensitivity and unidentified compounds which may not match available standards. Natural 
products such as Cannabis also contain other compound classes such as terpenes or enzymes 
that may skew data sets.  This introduces a need for methods that can eliminate or drastically 
decrease such matrix effects and allow the analysis of the target compound type. To optimise 
a method for cannabinoid analysis, three factors need to be considered: extraction, separation 
and detection. 
1.2.1 Extraction  
Extraction is the process by which desired compounds are separated from their matrix, 
mixture or starting material, in this case it is the active compounds (cannabinoids and 
terpenes) being extracted from the plant material. The matrix is comprised of any components 
that are not the analytes of interest; these compounds are ideally eliminated by extraction. In 
the case of plant material, the matrix includes solid material (leaves, flowers etc.), fats, cells, 
starch and chlorophyll44,58. Extraction of the analyte/s is usually achieved using a solvent in 
which the target compounds are soluble, in this case an organic solvent. For quantitative 
analysis, plant material samples need to be dried prior to any extraction3,5,17,18,22,31. This is due 
to the final concentration being reported as a percentage of the total dry plant material weight. 
The dry weight is necessary so that the water composition of the plant does not skew the 
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result, as water absorption differs between plants and through time. Extraction methods 
follow this drying step, or in the case of non-plant material samples, may be single or 
multiple step processes. 
The extraction process makes two assumptions. Firstly, that the initial extraction step extracts 
all cannabinoids. Secondly, that the cannabinoids extracted are recovered at approximately 
the amounts that they existed in the plant material, defined as a high recovery for target 
compounds. Extraction techniques are a vital process to the accurate determination of 
cannabinoid content in Cannabis. The extraction tools needed to decrease matrix effects 
while successfully extracting all intended compounds often require the use of multiple steps. 
Hazekamp (1976) published his PhD thesis Cannabis; extracting the medicine on extracting 
cannabinoids from Cannabis sativa29. Hazekamp (1976) looked at the extraction of many of 
the identified cannabinoids19 and followed other studies looking at the extraction from natural 
plant material, this was one of the first steps into attempting to completely and effectively 
extract the therapeutic compounds (cannabinoids) within Cannabis plant material. Little 
research has looked further at extraction processes for Cannabis derived products which are 
part of more complex or less defined matrixes. 
1.2.1.1 Single step extraction 
Single step extractions use a single solvent/solvent mixture before analysis. Examples of 
single step extractions include extraction with the buffer used for LC analysis or extraction 
with a volatile organic solvent for GC analysis59. Single step extractions are more prevalent 
in qualitative analysis and may not allow for the extraction of all desired compounds or the 
required recovery that is crucial for quantitative analysis. Single step methods have been 
documented and validated, however this research appears to exclusively report on THC 
content and few other cannabinoids4,5,60,61. Most research typically uses illicit plant material 
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that typically contains THC at such a high concentration that cannabinoids which are present 
at lower concentrations are not detected. For quantitative analysis, this technique may be 
useful for THC as this readily extracts into organic solvents3,5,20,24,35,40,44,62,63, if more 
cannabinoids are to be analysed then a more robust extraction method is required. 
1.2.1.2 Multiple step extraction 
Multiple step extractions use many different techniques including a range of solvents, and 
physical techniques such as filtration, evaporation or centrifugation to extract desired 
compounds. This can be followed by more diluents/solvents and repeated cycles. Multiple 
step extractions allow for the extraction of a range of compounds and can adjust for very low 
concentrations via concentration steps to vaporize the solvent or undesired matrixes. This 
does however introduce the need for an internal standard.  Multiple step extractions have an 
absolute requirement for an internal standard to track the change in target compound over the 
different steps. An internal standard is a chemical substance that is added to a sample at a 
known amount, to adjust for the volume of solvent used throughout the process of the 
extraction and thus any changes that may occur in sample concentration. Internal standards 
are usually chemically similar to the analytes of interest. D3-Δ
9THC is a common internal 
standard62,64 due to is very similar structure with the major psychoactive component, Δ9THC. 
Prazepam21,22 and Diazepam3,18 are other commonly used internal standards for Cannabis 
analysis, their structure is moderately similar to cannabinoids. During the process, the change 
in internal standard concentration is monitored and can therefore be compared to the 
compounds of interest. 
There is a great deal of literature on multiple-step extractions regarding Cannabis plant 
material3,17,18,21-24,35,38,40 including some research into intensive processes such as solid phase 
extraction (SPE)63 or ultrasound extraction65, however this is largely limited to the extraction 
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of cannabinoids. Processes that eliminate unwanted compounds may also remove other 
noteworthy compounds, such as the terpenes. There is also a lack of research into the 
extraction of cannabinoids and terpenes from Cannabis products, like oils, with complex 
biological compositions that may interfere with analysis of the target compounds. This is an 
area that requires more research, and ideally an extraction method suitable for multiple 
compounds, not just THC. This project does not have the scope to cover all of these 
extraction ideals, however future work could lead down this path. 
1.2.2 Chromatographic Separation Methods 
Chromatographic techniques are often the preferred method of separation in chemistry, using 
mobile and stationary phases to separate compounds. These phases have contrasting 
properties so that the analytes have a different affinity to each based on numerous things such 
as molecular shape, charged species and polarity. This causes them to separate based on the 
degree of affinity to a certain phase, and therefore the time taken to reach the detector after 
passing through a separation process is analyte specific. There are three main 
chromatographic techniques that have been used and validated across the world for 
cannabinoid and/or THC analysis; Thin Layer Chromatography (TLC), Gas Chromatography 
(GC) and Liquid Chromatography (LC).  
Separation techniques for Cannabis are well documented and have been extensively 
researched. There are many researchers in the area, however DeBacker et. al 200922 
identified a technique on which many researchers have based their work. The DeBacker et. al 
200922 method utilised the characteristics of 8 different neutral and acidic cannabinoids. In 
subsequent research, attempts were made to separate up to 9 cannabinoids2,17,18,20,24,35,40. Few 
studies have succeeded in the separation of greater than 10 cannabinoids21. Given the similar 
nature of their structures, it would be near impossible to successfully separate all 70 
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cannabinoids. However, given fewer than 15 cannabinoids are generally present in a single 
Cannabis based extract, this is not a major issue. The separation of the more common 
cannabinoid compounds with appropriate resolution is crucial for the analysis of Cannabis 
materials. Additionally, the technique must also be able to detect cannabinoids at low levels.  
1.2.2.1 Thin Layer Chromatography 
Thin layer chromatography (TLC) can be utilised in a forensic setting and in research to 
separate and identify THC in a given sample. A common TLC method utilises a silica solid 
phase and toluene as the liquid phase2,3,5. This interaction ensures that, with reference to an 
appropriate standard, the retention times are consistent. However, the identification of 
complex cannabinoid mixtures via retention time is very difficult due to the time restraint of 
the materials and similarities of the some of the compounds. The length of the solid phase 
used for TLC is a limitation that constrains the number of compounds that may be separated 
in any one sample, especially if the target compounds have a similar structure. The material 
constraints are due to the length of the silica plate, as similar structures require a lot more 
time using this method to separate, but a longer plate also has limitations. However due to the 
impracticality of the larger plates this is not an applicable method. Similar to liquid 
chromatography, this affinity is based on polarity effects. As a result, similar structures of the 
cannabinoid compounds make their separation using TLC difficult, as such it is 
predominately used as a screening test. 
 Identification of cannabinoids is based on the colour of the spot, after visualisation reagents 
are added. Visualisation is achieved for ten common cannabinoids using fast blue and sodium 
hydroxide however colour discrimination is limited2,3,5. This method turns the spots red, 
orange, brown or purple5 (Figure 1.6). This procedure can be relatively easy, fast and cost 
effective. However, the limitations can be identified by the inability to distinguish the 
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different cannabinoids and the higher concentrations needed to positively identify low levels 









1.2.2.2 Gas Chromatography 
Gas Chromatography (GC) is another well developed and widely accepted technique for the 
separation of cannabinoids and other non-cannabinoid components of Cannabis. GC utilises 
the boiling point of analytes to separate them, the boiling points of the eleven cannabinoids of 
interest are listed in table 1.266. It is both a fast and effective way to separate and detect 
individual cannabinoids from an extract.  Many manufacturers have developed columns and 
methods that are ideal for cannabinoids and their structure28,59,60,62,67 due to the demand for 
their analysis. Complex extracts are easily separated, making the identification of the 
individual cannabinoids ideal by GC, usually matched with mass spectrometry (MS) 
detectors2,3,5,20,21,24,35,40,44,62,63.   
 
Figure 1.6: Silica TLC plate 
with fast blue and sodium 
hydroxide to visualise. THC 
control on left and sample on 
right. 
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Table 1.2: Boiling points for eleven common cannabinoids: CBGA, THCA, CBDA, Δ9THC, 
Δ8THC, CBD, CBN, CBC, THCV, CBDV and CBG66. N/A refers to results that are not 
available. 













A difficulty with using GC techniques for cannabinoid analysis is the heat required to 
vaporise the sample. The GC inlet temperature of greater than 250°C means that the acidic 
compounds undergo decarboxylation readily3,5,20,21 and thus any peaks produced and 
identified are always the neutral species. This means that the peaks will often reflect the 
cumulative percentage of the acidic and neutral cannabinoids present3,20-22 in the material. 
However, it is usually necessary when a total THC content is required to add both acid and 
neutral together, but with medicinal or processed product that ideally contain intended 
individual amounts it is more important to distinguish the acid from the neutral2,18,22. More 
difficulties with GC techniques lie in the detection of peaks after separation, this can be seen 
in the separation section of this review. 
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1.2.2.2.1 Column Type 
The columns predominately used in GC cannabinoid analysis are capillary columns, often 
lined with silica-based stationary phases (dimethylpolysiloxane)22,62. This uses the same 
principle as TLC with the polar/non-polar properties being used as a separation technique 
along with boiling point. Another property of the column used, to further separate the 
cannabinoids, is a cross-linked and bonded stationary phase that adds the discriminatory 
factor of size. These columns have high temperature thresholds and utilise these three distinct 
factors to separate the cannabinoids. 
1.2.2.2.2 Derivatization 
Derivatization is an optional but ultimately useful step when analysing cannabinoids via 
GC5,62. This step allows the acid and neutral cannabinoids to remain individual compounds 
and as such be analysed separately. The active hydrogen groups, hydroxy groups, on the 
cannabinoids are replaced with larger functional group to form compounds with properties 
that are less polar and more stable in the experimental conditions, such as silyl groups which 
are a common derivatizing agent for GC/MS analysis5,48. Therefore, this derivative has 
altered properties which affects its elution from the column; size, boiling point and polarity. 
Derivatization is a costly step in terms of time and materials, and adds an additional variable 
to the analysis. A limitation of using derivatization is also that efficiency as 100% of the 
target cannabinoids may not be transformed. 
1.2.2.3 Liquid Chromatography 
Liquid chromatography (LC) is another widely used technique in component separation for 
mixtures. LC is ideal for cannabinoid analysis due to the lower temperatures, high pressure 
and high flow rates (if using HP or UPLC instrumentation). The use of low temperatures, in 
contrast to GC, allows the separation and detection of the individual acid and neutral 
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versions, without modification to the natural structure. Many authors have found LC columns 
that successfully interact with cannabinoids to separate them based on their structure and 
intrinsic properties. The foundation for many LC methods on cannabinoid analysis are based 
on the column type selected3,5,17-19,21,22,57,59,62. The column is similar for most studies, it is the 
conditions that can be altered which produces superior approaches to quantitation including 
larger linear ranges and more consistent calibration curves for both acidic and neutral 
cannabinoids. HPLC methods are now very well developed and capable of separating 8-10 
cannabinoids, both acidic and neutral3,18,22.  
1.2.2.3.1 Column Type 
The columns used predominantly for cannabinoid analysis are reverse phase hybrid (a 
hydrophobic solid phased comprised of inorganic and organic compounds) columns that 
boast pH stability3,22,59. There is successful separation of a range of different cannabinoids 
and/or terpenoids. Manufacturers and research studies are currently looking at column 
modifications, based on an LC column used in the DeBacker et al. 200916 method, to reduce 
run time and increase throughput. The column modifications maintain reverse-phase 
composition and a large pH range59. The dissimilarities lie in the pore size, column lengths 
and diameter. The technology to produce smaller pore sizes that aid with diffusion has 
increased the usability of these columns for cannabinoid work. 
1.2.2.3.2 Solvent system 
Most studies utilises a gradient system, this appears to be the key to separate these similar 
compounds. An isocratic buffer system is lacking in the quantitative literature; however, it is 
noted as the preferred system for THC identification and quantification5. An isocratic system 
uses a mobile phase of constant composition where as a gradient system alters the mobile 
phase composition over the course of the run. The experimentation methods shown by 
various researchers indicate different resolutions and retention times when the composition of 
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the solvent system is altered, thus reducing run time (coupled with different pressures and 
flow rates). A list of the common solvents used in research is listed in Table 1.3. Some 
buffers require an adjustment in pH while others just used different diluents and dilution 
levels to alter the affinity of the compounds to the mobile phases and promote separation. 
 






DeBacker et al. 
200922 and 201221 
Methanol 
50mM ammonium 
formate in water 
pH 5.19 
Gradient 








formic acid, pH 3 




Layton et al. 
201557 
0.1% formic acid in 
water 
0.1% formic acid in 
acetonitrile 
Gradient 








formic acid in water 
Gradient 





90% acetonitrile Gradient 
United Nations 
Office on Drugs 
and Crime 20095 
Acetonitrile Water Isocratic 
 
 
-  2 3  -  |  P a g e  
 
1.2.3 Detection 
The detection instrumentation linked with the separation technique (usually GC or LC) is a 
major component in the identification of Cannabis compounds. There are many ways to 
detect cannabinoids. The chromophores present have shown that ultraviolet (UV) detectors, 
such as photodiode array (PDA) detectors can be utilised, however mass spectrometry (MS) 
is the most informative and discriminating technique.  Flame ionisation detectors (FID) 
coupled with GC have also been used to identify cannabinoids24,68, however while this 
technique is sensitive, it does not provide structural information which may distinguish 
multiple cannabinoids in a mixture. 
1.2.3.1 Photodiode Array Detector 
Photodiode array (PDA) detectors use the chromophore absorption of the UV light by the 
cannabinoids to produce an ultraviolet (UV) spectrum. This detection method is very reliable 
at the optimal wavelength, and cannabinoids produce appropriate peak heights even at very 
low concentrations. DeBacker et al. 200916 used HPLC/PDA, which has been used in many 
subsequent studies3,17,18,21. Coupled with HPLC, this detection method can identify, based on 
retention time only, and quantitate cannabinoids over a large calibration range. UV spectra of 
the most common cannabinoids are available16,46, however data is limited. A limitation of this 
technique is the low discriminatory power due to the similarities of the UV spectra, this 
means that cannabinoids without a standard may have the same retention time and UV as a 
cannabinoid with a standard. Additionally, the spectra cannot be used to distinguish 
cannabinoids (Figure 1.7)19,22, leaving retention time as the only tool for identifying 
individual cannabinoids. Therefore, a second method is required to more accurately identify 
the cannabinoid present coupled with HPLC/PDA for better quantitative results. 
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1.2.3.1 Mass Spectrometry 
Mass spectrometry (MS) can be linked with both GC and LC separation methods. MS 
coupled with GC or LC provides discriminatory information based on unique ion 
fragmentation patterns37,44. GC/MS is most commonly used as a primary identification 
technique for Cannabis samples3,5,20,24,35,40,44,62,63, and it is the most researched technique for 
unknown cannabinoid mixtures. The characteristic ions for most cannabinoids have been 
documented (Figure 1.8)19 and placed in libraries in many commercial and research 
laboratories. This eases the identification of the cannabinoids. 
Figure 1.7: Ultra violet spectra of eight cannabinoids from DeBacker et al.  200922 study 
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GC can successfully separate similar cannabinoids to produce unique resolved retention times 
for each, and GC/MS has been used to quantitate total THC (inclusive of THCA) 
content2,3,5,19,65,69,70. However, MS techniques coupled with GC are limited for quantitative 
analysis of most cannabinoids due to breakdown when heated5,62. These pathways were 
discussed earlier as the decarboxylation of the primary acidic compounds and to a lesser 
extent the conversion of THC to CBN via degradation. Some cannabinoids are also difficult 
to detect at lower quantities using MS (especially if another cannabinoid is present at a high 
concentration), these lower amounts skew the spectrum causing similar cannabinoids to be 
identified. Therefore, while GC/MS is useful, these limitations indicate that LC/MS may be a 
more appropriate technique for simultaneous identification and quantitation20,71 as it would 
likely have the benefit of both LC and MS instrumentation. However, very few papers have 
researched this option in-depth, and fewer have attempted to profile a range of cannabinoids. 
Figure 1.8: Mass spectra of eight cannabinoids indicating characteristic ions from 
Hazekamp et al. 200519  
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Unfortunately, this project does not have full access to an LC/MS and thus this is a limitation 
on the extent of the instrumentation examined for cannabinoid analysis in the project.  
1.3 Aims 
The characteristics and effects of cannabinoids are a key area of research. Methodology that 
can identify and quantify the different components in Cannabis will play a crucial role in the 
growing medicinal Cannabis industry. There are three principal objectives that need to be 
optimised to achieve this ideal analysis of Cannabis and Cannabis-derived products: 
extraction, separation and detection. The aim of this research is to utilise the work of previous 
studies, their methods and instrumentation to derive a method that meets commercial and 
quality values and can profile Cannabis products in a succinct, effective, fast and reliable 
way.  
The specific aims of the project include: 
1. Development and optimisation of gas chromatography/mass spectrometry (GC/MS) 
conditions to separate 8 neutral cannabinoids and an internal standard D3-Δ
9THC. 
2. Development and optimisation of a liquid chromatography/photodiode array 
(LC/PDA) method to separate and quantify 11 cannabinoids. This will be the primary 
focus of the project. 
2.1 Validate this method using statistical analysis 
2.2 Use this method to analyse Cannabis samples in several types of media: 
such as low THC crops and oils. 
3. Investigation into the application of liquid chromatography/ tandem mass 
spectrometry (LC/MS/MS) for the analysis of 11 cannabinoids. 
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The analysis will focus around 11 common cannabinoids of interest using the instrumental 
techniques GC/MS and LC/PDA. LC/MS/MS will ideally be investigated in a small capacity 
due to the availability of the instrument. The 11 cannabinoids to be analyzed are: both Δ8 and 
Δ9 forms of THC; cannabidiol (CBD); cannabinol (CBN); cannabigerol (CBG), 
cannabichromene (CBC), cannabidivarin (CBDV), tetrahydrocannabivarin (THCV); and 
three acidic forms of cannabinoids, cannabigerolic acid (CBGA); cannabidiolic acid (CBDA) 
and Δ9 tetrahydrocannabinolic acid A (THCA-A). Δ9THCA-A will be referred to as THCA 
for the remainder of the thesis.  
The primary focus will be the development and validation of a comprehensive LC/PDA 
analytical approach for the detection and quantitation of 11 cannabinoids found naturally 
occurring in Cannabis. Instrumental conditions will be optimised to improve separation and 
determine the limit of detection and quantitation for each cannabinoid. Developing a 
LC/PDA method to successfully separate, detect and quantitate cannabinoids is critical to this 
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CHAPTER 2: GC/MS method development 
2.1 Introduction 
 GC/MS is an ideal starting point to investigate the analysis of cannabinoids. It has been used 
for many decades as a tool for qualitative and quantitative analysis of cannabinoids2,3,5,19,40.  
THC is usually the target for quantitative analysis whereas the other cannabinoids are usually 
only qualitatively analysed2,3,5,19,40. The first aim of this project was to develop a GC/MS 
method for the separation of eight neutral cannabinoids and an internal standard D3-Δ9THC. 
The acidic cannabinoids were not investigated due to the time constraints and the 
decarboxylation during the process of converting the sample to a gas that caused them to 
transform to their neutral forms. 
To investigate optimal conditions for GC/MS analysis of the 8 cannabinoids, the individual 
and mixed standards prepared were run on three different columns at seven different ramp 
rates to determine separation efficiency and resolution for each rate and column. The 
following sections will provide more details on the experimental conditions and the effect 
altering them had on the result. The initial and final temperatures were at 90 and 300°C 
respectively as these temperatures encompass all 8 cannabinoids boiling points. The 
individual and mixed acidic and neutral standards prepared were run to determine separation 
efficiency and resolution for each rate and column. 
2.2 Materials 
2.2.1 Instrumentation 
Analysis was undertaken using Agilent 5973 and 5975 GC/MS systems. 
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2.2.2 Chemicals 
The neutral cannabinoid standards: CBC, CBD, CBN, CBG, THCV, CBDV, Δ9THC, Δ8THC 
and D3-Δ
9THC in methanol and acidic cannabinoid standards: CBGA, CBDA and THCA in 
acetonitrile were obtained from Cerilliant (Texas, USA) at a concentration of 1.000±0.005 
mg/mL. 
Preparation of standard solutions was via weight and diluents were basic HPLC grade 
methanol (Scharlab, Gato Perez, Spain) and HPLC grade acetonitrile (Ajax Finechem, 
Auckland, NZ) for neutral and acidic cannabinoids respectively. Concentrations of mixed 
standards were 0.012 and 0.03 mg/mL for neutral and acidic cannabinoids respectively. All 
standards were stored at 4°C prior to analysis. 
2.3 Instrumental conditions 
2.3.1 Columns  
Changing a GC/MS column can alter peak resolution, peak shape, retention time and run 
time. The capillary columns tested were:  
• Column 1: Agilent 19091A-101, containing ultra 1 methyl siloxane (100% 
dimethylpolysiloxane). 12m x 0.200mm x 0.33 µm. Non-polar, bonded, cross-linked 
and solvent rinsible 
• Column 2: Agilent 122-3832, DB-35ms ((35%-phenyl)-methylpolysiloxane) Ultra 
inert. 30m x 0.25mm x 0.25µm. Intermediate polarity, bonded, cross-linked and 
solvent rinsible. 
• Column 3: Agilent 122-0732, DB-1701(14%-Cyanopropyl-phenyl)-
methylpolysiloxane). 30m x 0.25mm x 0.25µm Low-/mid-polarity, bonded, cross-
linked and solvent rinsible.  
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2.3.2 Ramp Rates 
A ramp rate is essentially a gradient elution, using a temperature programmed GC/MS.  
Changing the ramp rate allows compounds to elute at different times based on their boiling 
points, and changes the interactions of the compounds with the stationary or mobile phase at 
any given time. Ramp rates of 5, 10, 15, 20, 25, 30 and 35°C per minute were applied. 
2.3.3 Static Instrumental conditions 
The other instrumental conditions that were not changed during the course of the method 
development were as follows.  
2.3.3.1 Inlet 
The inlet was in splitless mode with a purge flow of 50mL/min and a purge time of 0.5mins 
with helium as a carrier gas. 
2.3.3.2 Mass Spectrum Parameters 
The MS source was electron ionisation (EI) with a mass selective detector. The transfer line 
used an initial and static temperature of 280°C. There was a solvent delay of 2.20mins and 
scan parameters use a low mass of 30.0 and a high mass of 550.0 and a threshold of 150. 
2.3.3.3 Initial and Final Temperatures and Injection volumes 
The initial oven temperature was 90°C with an equilibration time of 0.50mins and a final 
temperature of 300°C with a hold time of 15mins. The injection volume was 1µL. 
2.4 Results  
2.4.1 Columns 
All ramp rates method were trialed on three columns to optimise resolution of the peaks. 
Chromatograms from Column 1 indicated seven peaks that were identified via MS analysis 
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(Figure 2.1). The cannabinoids identified were CBDV, THCV, CBD, CBC, Δ8THC, Δ9THC 
and CBN; CBG and the internal standard D3-Δ
9THC did not produce visible peaks and were 
not identified via retention time. Column 2 provided separation and resolution for all eight 
neutral cannabinoids: CBDV, THCV, CBD, CBC, CBG, Δ8THC, Δ9THC and CBN; and the 
internal standard D3-Δ
9THC (Figure 2.2). During a subsequent run, the CBG peak in the 
mixed standard was no longer present, the CBC retention time and response decreased and 
the THCV response increased for Column 2 (Figure 2.2).  Injections of the single standards 
indicated CBG produced a single peak and CBC produced multiple peaks (Figure 2.3), with 
one of these peaks coeluting with THCV. Column 3 indicated low responses, broad peaks and 












Figure 2.1: GC/MS chromatogram of a ramp rate of 5°C/min using Column 1 to 
separate 8 cannabinoids. Peaks were identified via their mass spectra. 





















Figure 2.3: Chromatogram of cannabichromene standard 
on Column 2.  
Figure 2.2: GC/MS chromatogram of a ramp rate of 5°C/min using Column 2 to 
separate eight cannabinoids. Peaks were identified via their mass spectra. 
Chromatogram A displays all 8 cannabinoids with a shouldered peak that is the 
internal standard; Chromatogram B displays a subsequent run in which CBG and 
CBC peaks were no longer visible. 
 
B A 
Figure 2.4: GC/MS chromatogram of a ramp rate of 5°C/min using Column 3 to separate 8 
cannabinoids. Peaks were unable to be identified via their mass spectra as the individual 
cannabinoids.  
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2.4.2 Ramp rates 
Different ramp rates were tested on Columns 1 and 2, Agilent 19091A-101 and 122-3832 
respectively (Figure 2.5). Column 3 was not tested due to the low response observed in the 
previous study. The run times varied from 11 to 54 minutes, decreasing with increasing ramp 
rate.  Eight peaks were visible for rates 15, 20, 25, 30 and 35°C per minute and seven peaks 
for rates 5 and 10°C per minute. Via MS analysis (Figure 2.6) the eight peaks were identified, 
in retention time order, as CBDV, THCV, CBD, CBC, Δ8THC, Δ9THC, CBG and CBN and 
the seven peaks as CBDV, THCV, CBC, CBD, Δ8THC, Δ9THC and CBN. Ramp rates 20 to 
35°C/min displayed a slight co-elution for CBD and CBC. Similarly, rates 15 and 20°C/min 
displayed a split peak for CBG and CBN. The acidic cannabinoids CBDA, THCA and CBGA 
were run separately and indicated the same retention times and mass spectra as their neutral 
counter parts in each method. At a ramp rate of 5°C/min column 2, Agilent 122-3832, 
displayed a ninth peak shouldering Δ9THC which was identified via MS as the internal 
standard D3-Δ





























Figure 2.5: GC/MS chromatograms for ramp rates from 5 
to 35°C/min increasing in increments of 5°C/min using 
Column 1 to separate 8 cannabinoids: CBG, CBD, CBN, 
CBC, CBDV, THCV, Δ8THC and Δ9THC. 





















Figure 2.6: Mass spectra for 8 common cannabinoids: CBG, CBD, CBN, CBC, 
CBDV, THCV, Δ8THC and Δ9THC. 
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2.4.3 LoQ, LoD and Curves 
The LoD was determined using a S/N ratio of 3:1 using serial dilutions at 0.1, 1, 10, 100 and 
1000 ng/mL.  The LoQ and standard curves (Appendix 1) were determined using the area 
under the curve with injections of 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50 and 100µg/mL of 
individual standards and injections of 0.7125, 1.425, 2.85, 5.7 and 11.4µg/mL of the neutral 
cannabinoids mixed standard (Table 2.1). Due to the sigmoidal-like shape of some curves 
(Appendix 2), two correlation coefficients are provided (1st and 2nd) referring to linear ranges 
at lower and higher concentrations. THCV, Δ8THC and Δ9THC display only one r2 value as 
their linear range was consistent across both lower and higher concentrations. 
Table 2.1: GC/MS limits of detection, limit of quantification and linear range data for eight 
neutral cannabinoids of interest. Two r2 values are provided for some cannabinoids where 
two different linear ranges were apparent. 
 




Linear Range (µg/mL) 
1st 2nd 1st 2nd 
CBDV 0.9948 0.9985 1.00 2.85 2.85-11.40 6.25-50 
THCV 0.9991 0.71 0.71 0.71-100 
CBD 0.9923 0.9991 2.85 2.85 2.85-11.40 6.25-50 
CBC 0.9977 0.9971 2.85 2.85 2.85-11.40 6.25-25 
Δ8THC 0.9981 0.71 0.71 0.71-100 
Δ9THC 0.9981 0.71 0.71 0.71-100 
CBG N/A 0.9983 10 12.5 N/A 12.5-100 
CBN 0.9917 0.9979 1.42 2.85 2.85-11.40 6.25-25 
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2.5 Discussion  
GC/MS is a well-defined technique for cannabinoids analysis, having been used for decades 
for the identification of cannabinoids and the quantitation of THC. The aim of this part of the 
thesis was to alter established GC/MS conditions to optimise cannabinoid separation and 
provide information on the limitations of GC/MS as a technique for the quantification of 
multiple cannabinoids. This study provided a good introduction to optimising instrumental 
conditions and the effect simple changes could have on the resulting data. The initial and 
final temperatures were chosen to ensure elution of all compounds as the boiling points of the 
11 cannabinoids fell between 157 and 226°C (Table 1.2), but the full 11 cannabinoids could 
not be identified by this technique, due to decarboxylation of the acidic cannabinoids. This 
modification results in conversion to the neutral form of each cannabinoid, thus a maximum 
of eight peaks would be visible when analysing the 11 cannabinoids as observed in this study. 
A well-developed method to counter this effect is the use of derivatization in sample 
preparation5,62. This technique was not trialed due to time constraints and the acquisition of 
an LC/PDA which was the primary instrumentation for this thesis.  
2.5.1 Columns  
The columns used varied in composition and were selected from those already available. 
They were not purchased for the specific purpose of cannabinoid analysis, however did share 
similarities with columns recommended in other research. These properties include 
midpolarity and cross-linkage5,58,61,62,68. 
The differing properties of each column can account for the changes in retention times and 
elution order for the cannabinoids. The convergence of the CBC and CBD peaks on Column 
1 could be due to the non-polar nature of the stationary phase, as this type of column 
commonly cannot separate the two cannabinoids effectively60. Column 2 has mid-polarity 
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and was the most successful at separating all neutral cannabinoids at all ramp rates, although 
it did present a shouldered peak for the internal standard at a ramp rate of 5°C per minute. 
Similar structures made standard and deuterated Δ9THC difficult to separate, and provided a 
unique challenge. This problem could likely have been resolved with the use of a different 
column chemistry based on previous research5,58,61,62,68 however this was not within the 
budget nor the intention of the thesis. Alternatively, a different internal standard could be 
sourced. Column 2 was longer than Column 1, which is another possible explanation for the 
increased ability to resolve the peaks at all ramp rates, as the composition of Column 1 and 2 
is similar. The order of elution was similar for both columns, except for CBD and CBC which 
eluted in reverse order likely due to the differing polarities of the columns.  
The method required investigation into robustness due to the shifting retention times of CBC 
and CBG, possible explanations into the changes in retention time may be, CBC has 
approximately the same boiling point as THCV and thus a retention time shift closer to 
THCV is predictable, however the shift is difficult to explain as CBC and CBD can be 
difficult to separate60. The changes to retention time were able to be monitored and adjusted 
for with comparison to a reference standard. The new retention times have CBD and CBC 
more than 1.5 min apart. On inspection of the single CBC standard the compound now 
produced two peaks at 22.1 and 22.9 min, one of which co-eluted with THCV, explaining the 
increased response of THCV in the mixed standard. However, the breakdown of CBC 
causing the retention time shift and generating two peaks is an anomaly. In contrast, a single 
CBG standard indicated that the retention time had not changed nor had the response. 
Possible explanations for these aberrations could be structural rearrangements within the 
mixed standard, as CBGA is the primary precursor for all cannabinoids. In plant material 
cannabinoids degrade to different structural formations, which may occur in a mixed 
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environment due to adverse storage conditions, however this is unlikely as standards were 
refrigerated appropriately (4°C fridge). 
The composition of Column 3 is the most likely reason for the small response from each 
cannabinoid making them difficult to identify. The length, diameter and pore size are 
identical to Column 2, while the stationary phase was different, with low-/mid-polarity. The 
resulting peak tailing, small signal and irregular peak shapes made Column 3 unsuitable, 
although the fact that the peaks only appeared at ramp rate 5°C/min may indicate that this 
longer run time may have improved the response. This does however still indicate that 
Column 3 is less suitable of the three columns used. 
2.5.2 Ramp rates 
The changes in temperature ramp rates produced inverse effects, with the elution time of the 
cannabinoid decreasing with increasing temperature ramp. This is due to the boiling point of 
the compounds being reached more quickly. This change also effected separation of some 
compounds, as their boiling points were reported as ranges rather than single values. Boiling 
point ranges are likely to occur when an analyte takes time to fully evaporate once boiling has 
begun. Additionally, for some cannabinoids the boiling point appeared to change with the age 
of the standard. The documented boiling points for the 11 cannabinoids are in Table 1.2. 
Increasing the ramp rate caused the CBD and CBC peaks to co-elute in Column 1 and 2. This 
is due to the boiling point range of CBD and CBC in conjunction with the increased ramp 
rate decreasing the difference in retention time between each compound. Additionally, the 
compound structures are similar hence their interactions with the stationary phase are also 
similar. This effect made the 30 and 35°C rates not optimal. Similarly, for the slower ramp 
rates below 20°C per minute, the CBG and CBN peaks converged, eventually co-eluting 
completely at 5 and 10°C per minute. Thus the 25°C ramp rate was optimal using Column 1 
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due to all 8 peaks being present and appropriately resolved, although it did not resolve the 
D3-Δ
9THC internal standard. This is not optimal and further investigation into a different 
column or internal standard would be ideal.  
The elution order of the compounds was noteworthy, as it does not appear to coincide with 
increasing boiling point of the compounds. Other research has reported similar elution 
orders60,63. Counterintuitively, the cannabinoids appear to elute in descending order of boiling 
point, so that those with the higher boiling points elute first. This means that the column 
properties also play a significant role in the separation of the cannabinoids, rather than 
exclusively boiling point.  
2.5.3 LoD, LoQ and Curves  
The calibration curves were established over a large range (Appendix 1), and are suitable for 
quantification, via LoD, LoQs and correlation coefficients. The range at which each curve 
was linear differed greatly, likely due to the readiness of the compounds to ionise and 
producing a mass spectrum. For higher sample concentrations, the plateau is likely due to an 
overload on the instrumentation producing a sigmoidal-like shaped curve (Appendix 2).  
The LoQ observed was dependent on the linear range of the standard curve. The LoD in most 
cases, is equivalent to the LoQ, which is positive, as it means that compounds could be 
quantified down to their limits of detection. However, the different linear ranges due to the 
sigmoidal curve means that dilution factor must be used to fit within a specific curve. With 
values able to overlap each linear range the method needs more investigation into the 
accuracy of each curve and if overlapping values produce the same quantification result. 
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2.6 Conclusions 
The first aim of this study was to ascertain the effect of changing instrumental parameters on 
the separation of 8 neutral cannabinoids and an internal standard. The preferred method uses 
Column 2, Agilent 122-3832, a ramp rate of 5°C/min with an initial temperature of 90°C 
ramping to 320°C and holding for 15min. The run time is 42.25min with helium as the carrier 
gas. 
Using the equipment available, eight neutral cannabinoids were successfully separated and an 
internal standard was identified, albeit as a shouldered peak. The three acidic cannabinoids, 
not separated due to decarboxylation, produce an opportunity to work with derivatisation. 
Another opportunity to work further on the method is regarding the retention time shifts and 
co-elution of THCV, CBC and CBG. 
In a sample, THCV and CBC would be only able to be quantified if the other were not 
present. Alternatively, a technique with mass extraction capabilities such as LC/MS/MS 
could have the ability to distinguish the two coeluting peaks based on molecular weight. 
Another future scenario would be to calibrate CBG separately from the mixed standard to 
reduce the possibility of structural rearrangement within the mixed standard. 
Overall the method developed can separate CBN, CBDV, CBD, Δ8THC and Δ9THC and 
identify CBN, CBDV, THCV, CBC, CBD, Δ8THC, Δ9THC and CBN via MS with more 
work aimed at the validation of the quantitation method, including an additional internal 
standard method to adjust for extraction procedures.  
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CHAPTER 3: LC/PDA method development 
3.1 Introduction 
Liquid Chromatography -photodiode array (LC/PDA) is currently preferred for quantification 
of THC and other cannabinoid, primarily because it is a ‘softer’ analytical technique than 
GC/MS. While LC/PDA is the preferred method for cannabinoid quantification it does have 
limitations, such as the lower discriminatory power of UV spectra compared to mass spectra, 
leaving retention time in reference to a standard as the primary identification tool. This study 
will aim to use LC/PDA to develop a commercially viable and validated method for the 
separation and quantification of 11 cannabinoids in Western Australia (WA). A commercial 
method using LC/PDA is not currently available in WA, and with the rise in medicinal 
Cannabis usage and recent legalisation of prescription, this type of method is needed. The 
second aim of the project is to develop, optimise and validate a LC/PDA method for the 
analysis of 11 cannabinoids and use this to analyse Cannabis samples in low THC plant 
material and oil form. 
To investigate optimal conditions for LC/PDA analysis of the 11 cannabinoids, the individual 
and mixed standards prepared were run on one column using two different solvent systems 
and various gradients, flow rates and wavelengths to determine optimal separation and 
resolution. The column used was the Waters Xbridge C18, a widely published column similar 
to that used by DeBacker et al. 200922 and others. The use of a single column chemistry was 
due to budget constraints. The individual and mixed acidic and neutral standards prepared 
were analysed to determine separation efficiency and resolution for each ramp rate and 
column. 
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3.2 Materials 
3.2.1 Instrumentation and column 
Analysis was undertaken using an Agilent 1260 infinity II HPLC with a Waters Xbridge C18 
(4.6 x 150 mm, 3.5µm) column.  
3.2.2 Chemicals 
The neutral cannabinoid standards: CBC, CBD, CBN, CBG, THCV, CBDV, Δ9THC, Δ8THC 
and D3-Δ
9THC in methanol and acidic cannabinoid standards: CBGA, CBDA and THCA in 
acetonitrile were obtained from Cerilliant (Texas, USA) at a concentration of 1.000±0.005 
mg/mL.  
Preparation of standard solutions was via weight and diluents were the basic HPLC grade 
methanol (Scharlab, Gato Perez, Spain) and HPLC grade acetonitrile (Ajax Finechem, 
Auckland, NZ) for neutral and acidic cannabinoids respectively. Concentrations of mixed 
standards were 0.012 and 0.03 mg/mL for neutral and acidic cannabinoids respectively. All 
standards were stored at 4°C prior to analysis. 
Standard solutions of prazepam (Cerilliant, Texas, USA) and diazepam (Cerilliant, Texas, 
USA) used for internal standards were 0.01mg/mL each and previously prepared by staff at 
the ChemCentre. 
The first solvent system used 50mM ammonium formate solution (consisting of 3.15g of 97% 
ammonium formate (Sigma-aldrich, Louis Mo, USA) in 1L of deionized (DI) water brought 
to a pH of 5.19 using 98% formic acid (Chem-supply South Australia, Australia)) and 
methanol. The second solvent systems utilised formic acid to make 0.1% (v/v) formic acid 
solutions in both acetonitrile and DI water. 
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3.2.3 Control sample 
A hemp plant material control sample used was previously prepared by staff at the 
ChemCentre for analysis of a hemp case in 2009. Approximately 100mg was prepared in 5 
mL of ethanol for analysis. The control sample was one available and commonly used for 
THC analysis via GC/MS. 
3.3 Instrumental conditions 
3.3.1 Solvent system 
Buffer 1: The first buffer system trialled was from DeBacker et al. 200922. This used solvent 
A: methanol and solvent B: 50mM ammonium formate in water, pH 5.19 using formic acid. 
Buffer 2: The second buffer system used was cited in some technical notes from column 
producers Perkin Elmer57, Restek Corporation72 and Sigma Aldrich62. This used solvent A: 
0.1% formic acid in water and solvent B: 0.1% formic acid in acetonitrile. 
3.3.2 Gradient and Flow rate 
The gradient and flow rate were varied to alter the separation of the 11 cannabinoids. The 
first gradient used Buffer 1 and was longer than the following trials (Table 3.1). The 
following three attempts used Buffer 2 at varying flow rates to separate the cannabinoids 
(Table 3.2).  Following that, different gradient slopes with a static stop time and flow rate 
(Table 3.3) were implemented. The subsequent investigation used an increased run time 
(Table 3.4) and varied flow rates (Table 3.5). Trial 12 was an attempt to separate the acidic 
compounds (Table 3.6).  
The methods selected were Trial 3 at 0.8 mL/min for 8 min (Table 3.2) for neutral 
cannabinoids and Trial 12 at 0.8 mL/min for 15 min (Table 3.6) for acidic cannabinoids. A 
peak in the neutral method that was retention and UV matched to an acidic cannabinoid 
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would dictate that the acidic cannabinoids method then be run to quantify that peak which 
was CBDA and CBGA co-eluting in the neutrals method. This was not successful, as a 
mechanical fault caused retention time shifts. After the instrument was serviced, Trial 13 
(Table 3.7) was attempted using a combination of Trials 3 and 12, and a maximum of 95% 
acetonitrile to investigate if all 11 cannabinoids could be simultaneously separated under 
these conditions. 
 
Table 3.1: Gradient used for Trial 1 using Buffer 1 with stop time of 40mins and a flow rate 
of 0.3 mL/min. 
Time (min) %A %B 
0.00 68 32 
25.00 90.5 9.5 
26.00 95 5 
29.00. 95 5 
30.00 68 32 
36.00 68 32 
 
Table 3.2: Gradient used for Trails 2,3 and 4 using Buffer 2 with stop time of 8 min and flow 
rates of 1.0, 0.8 and 0.5 mL/min for Trials 2, 3 and 4 respectively. 
Time (min) %A %B 
0.00 25 75 
6.00 0 100 
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Table 3.3: Gradients used for Trial 5-9 using Buffer 2 with stop time of 15 min and a flow 
rate of 0.8 mL/min. 
Trial Time (min) %A %B 
5 
0.00 25 75 
8.00 0 100 
8.01 25 75 
6 
0.00 25 75 
10.00 0 100 
10.01 25 75 
7 
0.00 50 50 
5.00 25 75 
10.00 0 100 
10.01 25 75 
11.00 50 50 
8 
0.00 50 50 
3.00 25 75 
10.00 0 100 
10.01 25 75 
14.00 25 75 
14.01 50 50 
9 
0.00 50 50 
3.00 25 75 
8.00 0 100 
10.00 0 100 
15.00 50 50 
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Table 3.4: Gradient used for Trial 10 using Buffer 2 with stop time of 20 min and a flow rate 
of 0.7 mL/min. 
Time (min) %A %B 
0.00 50 50 
5.00 25 75 
12.00 0 100 
12.01 25 75 
19.00 25 75 
19.01 50 50 
 
Table 3.5: Gradient used for Trial 11 using Buffer 2 with stop time of 20 min with varying 
flow rate as indicated. 
Time (min) %A %B Flow rate (mL/min) 
0.00 50 50 1 
5.00. 25 75 0.8 
1200 0 100 0.7 
12.01 25 75 0.7 
19.00 50 50 1 
 
Table 3.6: Gradient used for Trial 12 using Buffer 2 with stop time of 12 min and a flow rate 
of 0.8 mL/min. 
Time (min) %A %B 
0.00 50 50 
5.00. 25 75 
10.00 0 100 
10.01 0 100 
11.00 50 50 
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Table 3.7: Gradient used for Trial 13 using Buffer 2 with stop time of 13 min and a flow rate 
of 0.8 mL/min. 
Time (min) %A %B 
0.00 50 50 
5.00 25 75 
10.00 5 95 
10.01 5 95 
12.00 50 50 
 
3.3.3 Temperature 
Three temperatures were used based on those in the literature 30°C3,22, 35°C62 and 50°C57,72. 
3.3.4 Wavelengths 
Two wavelengths were used based on popular literature 2283,22 and 270 nm3,22. 
3.4 Results  
3.4.1 Experimental condition optimisation 
All peaks were identified using retention time, as the UV spectra were unable to be used as 
identification techniques due to the spectra from each individual cannabinoid being very 
similar (Figure 3.1). Buffer 1, along with gradient Trial 1(Table 3.1) at 30°C on wavelengths 
228 and 270 nm produced 7 peaks when running the neutral cannabinoids mixed standard and 
3 peaks when running the acidic cannabinoids mixed standard (Figure 3.2). CBG and CBD 
were observed to co-elute at 27.9min. The baseline for 228 nm was negatively linear drift, but 
this wavelength did generate a greater response from all cannabinoids. If the acidic and 
neutral cannabinoids were to be injected together. THCA and THCV and CBGA and CBDV 
would have similar retention times and may produce a wide peak due to co-elution.  





















Figure 3.1: Ultra violet spectra of 11 cannabinoids of interest using LC/PDA. 



































Figure 3.2: LC/PDA chromatogram of three acidic cannabinoids (A and B) and eight 
neutral cannabinoids (C and D) using solvent system one and gradient system one at 
two wavelengths: 228nm (A and C) and 270nm (B and D) 
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The first attempt using Buffer 2, utilised the trial gradient in Table 3.2, a temperature of 
50°C, flow rate of 1 ml/min and the wavelengths 228 and 270nm (Figure 3.3). The 
compounds of interest eluted between 3 and 6 min. There were 10 peaks observed, with 
CBDA and CBGA co-eluting at 4.4 min. Δ8 and Δ9 THC co-eluted at all flow rates tested. 
Flow rate was reduced to 0.8 and then 0.5 mL/min to attempt to reduce co-elution and 
shouldering, however this simply increased the retention time of all of the peaks. Similarly, 
lowering the column temperature to 35 and then 30°C did not improve the separation by 
reducing back pressure. Using the same solvent ratios, the time taken to reach 100% solvent 
B was increased from the original 6 min to 8 and 10 min (trails 3, 5 and 6 respectively), but 
this did not alter the co-elution or shouldering and again simply increased the retention time 


















Figure 3.3: LC/PDA chromatograms using Buffer 2, the trial gradient in Table 3.2 with a 
flow rate of 0.8mL/min and temperature of 35°C to separate 11 cannabinoids. Peaks 
were identified by retention time match to individual cannabinoid standards. 
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Setting the gradient to start at 50:50 solvent A and B was trialled to attempt to separate 
CBGA and CBDA at the beginning of the run (Trials 7-13). CBDA and CBGA were 
successfully separated, CBC and THCA now co-eluted at 11.3 mins (Figure 3.4). 
Additionally, the split peaks for Δ8 and Δ9 THC still occurred. The retention times for the 















Figure 3.4: LC/PDA chromatograms using Buffer 2, gradient trial 7 (Table 3.3) with a flow 
rate of 0.8mL/min and a temperature of 50°C to separate 11 cannabinoids. Peaks were 
identified by retention time match to individual cannabinoid standards. 
-  5 3  -  |  P a g e  
 
 
To attempt to resolve the co-elution of CBC and THCA a more gradual gradient back to 
25:75 and 50:50 A:B was trialled (Trials 8-10). This was unsuccessful and did not alter the 
chromatogram. Trial 9 reduced the gradient slope from 50:50 to 25:75 A:B was also trialled 
at 3 min to determine whether the CBGA and CBDA would still separate, but this was also 
unsuccessful and did not alter the chromatogram. 
Trial 10 attempted to separate CBC and THCA was to increase the run time and hold at 25:75 
A: B and decrease the flow rate, however CBC and THCA still co-eluted. Trial 11 altered the 
flow rate during the gradient. This successfully separated 11 cannabinoids with split peaks for 
CBDA and CBGA, Δ8THC and Δ9THC, and CBC and THCA. Trial 12 attempted an 
increased decline from 100% B to 50:50 A:B to attempt to separate Δ8 and Δ9 THC at the end 
of the run, this had no effect. Unfortunately, the chromatograms also showed considerable 
peak tailing and a very noisy baseline. The retention times were between 7.5 and 12 minutes. 
Finally, after an instrument service and a slight change in gradient to Trial 13 (Table 3.7), 
Buffer 2, with a run time of 13 min and a column temperature of 50°C using 228 and 270nm, 
successfully separated and detected all 11 target cannabinoids (Figure 3.5). The retention 



























Figure 3.5: LC/PDA chromatograms using Buffer 2, gradient trial 13 (Table 3.7) 
with a flow rate of 0.8mL/min and a temperature of 50°C to separate 11 
cannabinoids. Peaks were identified by retention time match to individual 
cannabinoid standards. Both 228 and 270 nm were used.  
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3.4.2 LoD, LoQ and Curves 
The limit of detection (LoD), limit of quantification (LoQ) and standard curves were 
determined via a series of injections. The neutral cannabinoid standards were injected at 
1.2x10-3, 2.4x10-3, 3.0x10-3, 6.0x10-3, 1.2x10-2, 2.4x10-2, 3.6x10-2, 4.8x10-2, 0.06, 0.09, 0.12, 
0.18 and 0.24mg/mL; and the acidic cannabinoid standards were injected at 3.0x10-3, 6.0x10-
3, 7.5x10-3, 1.5x10-2, 0.03, 0.06, 0.09, 0.12, 0.15, 0.18, 0.225, 0.24 and 0.3mg/mL (Table 3.8). 
The LoD was visually observed using the lower concentrations values, but also determined 
via a signal-to-noise (S/N) ratio of 3:1. Similarly the LoQ was determined using the lowest 
value on the calibration curve which has a S/N ratio greater than 10:1.  The standard curves 
(Appendix 3) were determined using the area under the curve for the different injection 
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Table 3.8: LC/PDA limits of detection and quantification and linear range data for 11 neutral 
cannabinoids of interest. r2, LoD and LoQ values are provided for each cannabinoid at each 
wavelength used: 228 and 270 nm. 
 
3.4.3 Internal standard/s 
Three internal standards were trialled. D3-Δ
9THC had the same retention time as Δ9THC 
(11.1 min) and prazepam and diazepam had similar retention times at 2.6 and 3.2 min, 
respectively (Figure 3.6). 
 




270nm 228nm 270nm 228nm 270nm 228nm 
CBDV 0.9990 0.9998 2.4 6.0 3.0 6.0 
CBDA 0.9999 0.9993 0.45 6.0 3.0 7.5 
CBGA 1.0000 0.9999 0.35 6.0 3.0 7.5 
CBD 0.9922 0.9991 2.4 6.0 3.0 6.0 
CBG 0.9969 0.9986 2.4 6.0 3.0 6.0 
THCV 0.9986 0.9984 2.4 6.0 3.0 6.0 
CBN 1.0000 0.9995 0.37 3.0 3.0 6.0 
Δ9THC 0.9998 0.9998 2.4 6.0 3.0 6.0 
Δ8THC 0.9999 0.9994 2.4 6.0 3.0 6.0 
CBC 0.9997 0.9999 0.5 3.0 3.0 6.0 
THCA 0.9998 0.9991 0.33 6.0 3.0 3.0 





















Figure 3.6: LC/PDA chromatograms and UV spectra of possible internal standards: 
diazepam, prazepam and D3-Δ
9THC. Obtained using Buffer 2, gradient 13 (Table 
3.7) and a temperature of 50°C. Co-elution of D3-Δ
9THC with Δ9THC was 
determined pre-instrument service. 
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3.5 Discussion 
LC/PDA is a useful technique that is used in a range of different analytical contexts and has 
been shown to be a valuable tool for the quantification of cannabinoids in plant mediums. 
The aim of this part of the project was to separate 11 cannabinoids by optimising method 
conditions such as buffer mixtures, gradient, flow rate and column temperature. From this 
foundation a method for the quantification of all 11 cannabinoids would ideally be 
constructed. Due to instrument faults and time constraints the amount of data produced for 
the final method is limited and thus any values are approximate and subject to further 
validation. The methods preceding this optimized method will be discussed in part as they 
provide data useful for understanding method development and validation. 
3.5.1 Column  
Assessment of column chemistry was limited by the budget, which only allowed for the 
purchase of one column. This column was chosen after research into columns used in 
previously published methods, and other columns were considered, but the majority has the 
same basic properties. These include being C18 reverse phase columns, with a large pH range. 
The use of only a single column remains limitation to this experiment, as other column 
chemistries could have provided greater insight into the separation of the cannabinoids and 
allowed for further manipulation of the method. Modification of column length or pore size 
has been considered in numerous LC/PDA method development papers, with greater budget 
and time should be more extensively explored. 
3.5.2 Buffer 
The buffer systems trialled were derived from various sources, with most using a mixture of 
acetonitrile, formic acid, water and/or methanol. The initial buffer system was adopted from 
DeBacker et al.22, however the amount of co-elution and the long run time were 
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disadvantages, so an alternative buffer combination was sought. This second system was able 
to separate all 11 cannabinoids and in about one-third of the run time. This is important from 
a translation perspective, as it increases the potential throughput of the method. The solvents 
selected for Buffer 2 were more effective for separation, time and ease of preparation. 
Buffers are pH-dependent and often need to be adjusted to a certain pH, however this 
particular buffer did not require a pH adjustment. When inconsistent retention times were 
encountered, the shelf life of the buffer and its pH stability were investigated, using an 
internal standard could adjust for this by using a relative retention time (RRT). As the buffer 
has been widely used in the literature, it was assumed to be stable and this was confirmed by 
this study, which determined it to be very stable over time in terms of pH and by extension 
concentration. Acetonitrile is a stable solvent with a high boiling point which tends to rule out 
evaporation and the system was closed which rules out addition of CO2. Acetonitrile was also 
important in keeping back pressure low, as the high flow rate contributed to the back 
pressure. 
The first buffer system could potentially have been optimised to separate the co-eluting 
compounds, however it was decided to try an alternative buffer system instead. The second 
buffer system was chosen because it successfully separated 10 of the 11 compounds through 
initial experiments in less than 15 min, compared to 7 of the 11 compounds in ~40 min.  
3.5.3 Flow rate 
The next conditions to be manipulated were the gradient and flow rate, with the flow rate 
mostly affecting the time at which the compounds eluted. The results from the initial gradient 
for Buffer 2 (Table 3.2) indicated that optimisation of the flow rate or gradient would be 
needed to separate all 11 cannabinoids and improve resolution. Flow rate was reduced to 
separate the co-eluting acids CBDA and CBGA, and to improve resolution between Δ8 and Δ9 
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THC. It was suspected that a lower flow rate would ultimately allow the co-eluting 
compounds CBDA and CBGA to separate effectively, but this was not the case. As such 0.8 
mL/min was selected as it provided an efficient run time with the other cannabinoids being 
effectively resolved. While 0.5 and 1 mL/min did improve separation, the resolution at 0.8 
mL/min was acceptable and time efficient when resolving the nine cannabinoids. While the 1 
ml/min flow rate was faster and thus more time efficient, it did compromise the resolution of 
the peaks Δ8 and Δ9 THC. 
3.5.4 Gradient 
Use of a gradient system has been more popular than isocratic systems, and shown to be 
effective in various published studies (Table 1.3); for this reason, an isocratic system was not 
tested and a known gradient system was used as a starting point. DeBacker et al.22 analysed 
and separated 8 cannabinoids: Δ8THC, Δ9THC, CBN. CBD, CBG, CBGA, CBDA and 
THCA. This study attempted to add CBC, CBDV and THCV to the method in an attempt to 
broaden the range of cannabinoids able to be quantified and keep pace with the medicinal 
Cannabis industry. The first attempt using this method, albeit with a slightly different 
column, separated 8 cannabinoids (Trial 1). THCV and THCA, and CBDV and CBGA had 
very similar retention times with less than 0.5 min difference between the pairs, which would 
cause co-elution or a split peak if the acidic and neutral cannabinoids were to be analysed 
simultaneously. Additionally, the separation of CBD and CBG was not complete in this 
attempt, whereas the original DeBacker et al.22 method was able to separate these two 
compounds. This difference was likely due to the difference in the column used, as the 
Waters Xbridge is shorter with a larger diameter and smaller pore size. 
Subsequent gradients using Buffer 2 used a process of trial and error (Trial 2-13). The new 
gradients and buffer system allowed the previous co-elution of CBG and CBD; THCV and 
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THCA; and CBDV and CBGA to be rectified, but generated other chromatographic issues.  
CBDA and CBGA now co-eluted and THCA would likely create a split peak with CBC. As 
would Δ8 and Δ9 THC meaning that the acidic and neutral cannabinoids could not be mixed 
for analysis. A decrease in the slope of the solvent gradient (from 0 - 6 to 0 - 8 and 0 – 10 
min) was trialled to slow the rate of mixing of the buffer, which was expected to improve the 
separation of the peak. However, CBDA and CBGA still co-eluted, and retention times for 
CBC and THCA still overlapped.  
The subsequent gradient started with a 50:50 ratio of A: B, and gradually changed to 25:75 
and then 0:100. This modified the gradient for those compounds eluting earlier in the run, as 
they experienced a more aqueous (polar) mobile phase. This proved successful in separating 
CBDA and CBGA. The increase in the aqueous content of the mobile phase likely aided the 
separation of the acidic compounds early in the analysis as the carboxy groups will have 
increased their affinity to the more polar solution. This change did however cause the THCA 
and CBC to co-elute at the end of the run, rather than create a split peak.  This necessitated 
alteration of the later part of the gradient elongating the 25:75 ratio and decreasing that 
gradient by again increasing run time. This successfully eluted all 11 cannabinoids in 13 min. 
Slight split peaks were still apparent for CBDA and CBGA; Δ8 and Δ9THC; and THCA and 
CBC, however the retention time differences allowed the peaks to be sufficiently resolved for 
data analysis. The two wavelengths trialled did indicate different responses and peak tailing, 
suggesting that other wavelengths may improve the resolution of these compounds. 
It was suggested during instrument maintenance that the low viscosity of the acetonitrile may 
be contributing to retention time shifts by interfering with the operation of the HPLC pump. 
For this reason, the highest A:B ratio was changed to 5:95 instead of 0:100 due to the nature 
of acetonitrile. The 5:95 ratio produced results very similar to the 0:100 ratio, and so it was 
adopted into the final method to reduce the likelihood of issues being caused by the 
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acetonitrile. An isopropanol wash was added at the beginning of every run to flush the system 
of any remaining acetonitrile.  
3.5.5 Temperature  
Published methods have used column temperatures between 30 and 50°C3,22,57,62,72, so a 
temperature of 50°C was selected. Other temperatures were assessed, however this made 
little difference to the resulting chromatograms. Further investigation into the effects of 
varying column temperature on the chromatograms could be undertaken, however the number 
of methods using temperatures in this range suggests that it is an optimal temperature. A 
recent blog by Phenomenex on the matter indicates that temperature does little to affect the 
elution of the cannabinoids73. Temperature is primarily a tool to reduce back pressure in 
HPLC systems. 
3.5.6 Wavelengths  
Wavelengths of 228 and 270 nm were trialled on the basis of previous literature, which 
suggested that 228 nm was better for neutral cannabinoids and 270 nm for acidic 
cannabinoids3,22. The baseline for 228 nm was always sloped, initially causing substantial left 
peak tailing. This may have been due in part to a fault in the instrument, as it was rectified 
after the instrument was serviced. This tailing proved problematic when it came to peaks with 
similar retention times, as the tailing meant that the later eluting peak gained area under the 
curve.  However, the response signals for 228 nm were greater in area in comparison to 270 
nm, so it was a useful wavelength for detection. 270 nm did not show a greater response for 
acidic cannabinoids, unlike reports from the literature. The acidic cannabinoids, THCA, 
CBDA and CBGA did have a greater response in general when compared to the neutral 
cannabinoids, as did CBN and CBC, whose responses were greater than that of the other 
neutral compounds despite being present at the same concentration. This was likely due to the 
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response of the differing chemical structures PDA detection, as the UV spectra indicated 
greater responses at 228 nm than 270 nm (Figure 3.1)  
The method allowed for both wavelengths to be calibrated. While both were viable, they did 
have different LoD and LoQ values, which will be discussed in a later section. 270 nm had a 
flatter baseline and uniform peak shapes, however 228 nm did have advantages when it 
comes to larger response values, providing greater discrimination of small changes in 
concentration.  
3.5.7 LoD, LoQ and standard curves 
The LoD and LoQ for cannabinoid analysis via LC/PDA were higher, by at least 10-fold, 
than in previous studies21,22,57 (Table 3.9). The method is still fit-for-purpose, as a LoQ of 3 
µg/mL is equivalent to 0.015% w/w of cannabinoid/Cannabis product if 5 mL of diluent is 
used for 100 mg of sample. This value is appropriate for the analysis of total THC in hemp 
samples, as it is below the legal limit of 0.3% w/w. The LoD and LoQ for the different 
cannabinoids differed slightly likely due to the wavelengths used. All data was determined in 
duplicate and thus more results should be accumulated to assess the certainty and precision. 
The LoD and LoQ for the different wavelengths only differed slightly, despite the area counts 
by as much as 6-fold (Table 3.8). This is interesting as 228 nm generated a much greater area 
under the curve when compared to 270 nm, which would suggest that it could provide greater 
sensitivity, but this was not the case.  
Overall, both wavelengths provided sufficient correlation coefficients, and y-intercepts that 
were close to zero. The final method was only run in duplicate, however the other methods 
used in this suggested appropriate reproducibility and fit-for-purpose results. 
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Table 3.9: Comparison of limits of detection of various cannabinoids in this project to 
previous recent research. N/A refers to cannabinoids not quantified in that study. 
 LoQ (µg/mL) 
Cannabinoid/Study DeBacker et al. 
200922 and 
201221 
Layton et al. 
201557 
This project 
CBDV N/A N/A 3.0 
CBDA 0.125 N/A 3.0 
CBGA 0.125 N/A 3.0 
CBD 0.1875 0.106 3.0 
CBG 0.375 0.102 3.0 
THCV N/A N/A 3.0 
CBN 0.125 0.183 3.0 
Δ9THC 0.125 0.112 3.0 
Δ8THC N/A N/A 3.0 
CBC N/A 0.273 3.0 
THCA 0.125 0.592 3.0 
 
3.5.8 Internal standards 
The use of an internal standard is integral to a method such as this, and allows the 
quantification of cannabinoids in difficult matrixes such as oils or butters, as any loss of 
compound through the extraction method could be adjusted for with the internal standard. 
The internal standards investigated include D3-Δ
9THC, prazepam and diazepam. D3-Δ
9THC 
was found to be unsuitable due to the nature of the compound; it is very similar to Δ9THC 
and the two compounds co-eluted. Prazepam and diazepam were both suitable as internal 
standard for the method, as they eluted before all 11 cannabinoids and have been confirmed 
as suitable by previous studies3,18,21,22.  
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3.5.9 Photodiode Array Detector 
The LC was coupled with a PDA detector, as it is appropriate to measure cannabinoids based 
on previous literature, and also because of instrument availability. LC/PDA is a documented 
technique for the analysis of cannabinoids, and as such was a valuable technique to 
investigate, but it does have limitations. Identification of the individual cannabinoids was 
purely based on retention time, as the UV spectra of the cannabinoids were very similar 
(Figure 3.1), and thus provided little to no discriminatory power. Similarly, cannabinoids 
without a reference standard cannot be identified from a database of known UV spectra. This 
makes samples with cannabinoids that are not matched to a primary or secondary standard 
unable to be positively identified as anything other than a cannabinoid-like spectrum.  A 
suggestion for this would be to use a detector such as a mass spectrometer for the 
identification of the cannabinoids, due to its discriminatory power using ion fragmentation; 
this could be coupled with GC or LC. Due to the restrictions of GC identified in the previous 
section, LC/MS would be a worthwhile avenue to explore. 
Similarly, as mentioned in the GC/MS section, if other cannabinoids that do not have a 
reference standard are present in the sample and co-elute with a cannabinoid referenced in the 
method the PDA has no way of discriminating between them, so a method with mass 
discrimination would be preferred. Identification of the cannabinoids being based only on a 
retention time match to a reference standard was particularly relevant to this project as 
retention time shifts were observed throughout the study. This made it very difficult to 
identify peaks using retention time, and also reduced reproducibility and peak precision. This 
also affected our ability to automate the method, with a stated aim being to make a 
commercially viable and efficient method. 
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3.5.10 Comparison to other LC/PDA methods 
Comparison of this method with other LC/PDA methods (Table 3.10) supports the continued 
use of this instrument to analyse cannabinoids. This method attempts to quantitate many 
cannabinoids in a commercial quantitative setting quickly and effectively, and compared to 
other studies, the ability to analyse 11 cannabinoids is an important achievement. 
Table 3.10: Comparison of the number and retention times of cannabinoids in this study to 
previous studies. N/A denotes the cannabinoids that are not included in the studies. 
 










































































8 N/A 10.7 12.4 16.5 17.1 N/A 21.0 23.5 24.3 N/A 18.5 
Layton et 
al. 201557 
6 N/A N/A N/A 5.2 5.0 N/A 6.1 6.7 N/A 7.4 7.7 
Swift et 
al. 201318 
9 N/A 6.0 6.5 8.6 8.1 9.2 12.2 14.7 N/A 18.2 13.4 
 
The elution orders reported in different studies were similar to this one, probably due to the 
solvent systems (Table 1.3) and columns used (Table 3.11). The solvent system used by 
Layton et al.57 was identical to that used in this study, and the elution order was the same, 
except for CBD and CBG, which eluted in the opposite order. Small differences in the 
column and gradient used may account for this, but these differences were necessary, as this 
study attempted to analyse an additional 5 cannabinoids. Swift et al.18, used an identical 
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column to this study, and their results differed again in the elution order of CBD and CBG, as 
well as THCA, which eluted much earlier in Swift et al.18. That study18 also reported the 
highest number of cannabinoids analysed compared to this study, however it did use a longer 
run time and different solvent and gradient system. Two studies by DeBacker et al.21,22 were 
the most divergent, with the column being longer with a smaller diameter and larger pore 
size, and a contrasting solvent system. These studies were the starting point for much 
subsequent research, and as such more recent literature has considerably enhanced the 
original DeBacker et al. method21,22. The first attempt in this study to emulate the DeBacker 
et al. method21,22 was unsuccessful likely due to the use of a shorter column, however it did 
aid the understanding of the analytes and the system being used. 
 
Table 3.11: Comparison of the column properties used for LC analysis of cannabinoids in this 
and previous studies. 
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3.6 Conclusions 
The second aim of this thesis was to develop and optimise a method for the separation of 11 
cannabinoids using LC/PDA. Separation of these 11 cannabinoids was achieved, with peaks 
resolved an identifiable, in spite of some similarities in retention times. The final method uses 
a C18 reverse phase column, at a temperature of 50°C, with a flow rate of 0.8 mL/min and a 
gradient system (Table 3.7) with buffers of 0.1% formic acid in acetonitrile and 0.1% formic 
acid in water. This was found to be the best method based on optimized conditions of 
gradient, flow rate, buffer, temperature and an option for two wavelengths, and was largely 
only restricted by the column available. Further experimentation with different columns 
would be ideal, however the method does successfully separate and quantify the 11 target 
cannabinoids. Similarly, the use of a PDA detector is a limitation of this method due to its 
inability to distinguish between different cannabinoids, and as such a more discriminatory 
detector should be explored. The method was also not validated due to time constraints, so 
any conclusions and data should be validated using a series of separate runs to fully 
determine reproducibility, precision and measurement uncertainty. However, the method is 
promising as good as, if not better than previously published methods. With further 
exploration into the internal standards and validation the method will be fit-for-purpose and 
able to quantitate 11 cannabinoids. 
3.6.1 Final method 
3.6.1.1 Instrumentation 
Analysis was undertaken using an Agilent 1260 Infinity II HPLC system. 
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3.6.1.2 LC/PDA conditions 
Table 3.12: Optimised LC/PDA method parameters for cannabinoid analysis. 
Column: Waters Xbridge C18 reverse phase, 4.6 x 150 mm, 3.5 µm 
Mobile phase: Solvent A: 0.1% formic acid in water 
Solvent B: 0.1% formic acid in acetonitrile 
Solvent Gradient: 
Time (min) %A %B 
0.00 50 50 
5.00 25 75 
10.00 5 95 
10.01 5 95 
12.00 50 50 
 
Analysis time: 13 min; initial equilibration time of 15 min 
Flow rate: 0.8 mL/min 
Pressure: 140 bar maximum 
Column temperature: 50° 
PDA detection: Wavelengths: 228 and 270 nm 
Injection volume: 5 µL 
 
3.6.1.3 Samples and sample preparation 
Plant material and oil samples were provided by the Chemistry Centre of WA. Plant material 
samples were submitted to the ChemCentre by the WA Police (WAPOL). Hemp samples 
were provided by hemp companies to the ChemCentre. 
100 mg of sample (plant material or oil) was weighed and sonicated for a minimum of 8 min 
in 5 mL ethanol (Scharlab, Gato Perez, Spain). Samples were further diluted with ethanol to a 
final dilution of 50-fold. This can be adjusted according to the strength of the sample so to fit 
the calibration curve. 
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Chapter 4: LC/MS/MS method development 
During the period when the LC/PDA was under repair, an LC/MS/MS became available and 
granted the opportunity to explore a technique that theoretically incorporated the best of both 
previous techniques trialled, GC/MS and LC/PDA.  
4.1 Instrumental conditions 
Analysis was undertaken using a ThermoScientific Vanquish UHPLC and Velos Pro MS/MS 
with a electron spray ionisation MS source, and a scanning range of 100-500 in full scan 
mode, total ion current (TIC). 
Individual and mixed cannabinoid standards were prepared as described in 3.2.2, and injected 
at 1 and 20 µl. 
The method parameters from the LC/PDA were transferred to the LC/MS/MS, as the basis of 
separation is the same, it is only the detector that has changed. 
Table 4.1: LC/MS/MS Method Parameters. 
Column: Waters Xbridge C18 reverse phase, 4.6 x 150 mm, 3.5 µm 
Mobile phase: Solvent A: 0.1% formic acid in water 
Solvent B: 0.1% formic acid in acetonitrile 
Solvent Gradient: 
Time (min) %A %B 
0.00 50 50 
5.00 25 75 
10.00 5 95 
10.01 5 95 
12.00 50 50 
 
Analysis time: 13 min; initial equilibration time of 15 min 
Flow rate: 0.8 mL/min 
Column temperature: 50°C 
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4.2 Results 
The individual cannabinoid standards and mixed standards, both neutral and acidic, were 
injected at 1 µl with reference blanks. No peaks were detected in any of the standards, with 







Subsequent analysis used 20 µl injections of the individual and mixed standards, with blanks 
for reference. Individual standards of each cannabinoid displayed irregular peak shapes. 
THCA produced 2-3 integrated peaks, with one peak being split, along with peak 
shouldering. CBD, CBN, CBG, CBDV, CBGA, CBDA, Δ8THC, Δ9THC and THCV 
produced a single peak with visible shouldering. THCV, CBDA, CBN and CBD had small 
additional peaks that were substantially higher in intensity than the baseline noise. CBC 
produced a single peak with no shouldering. 
7 of the 8 cannabinoids produced visible peaks in the neutral cannabinoids mixed standards: 
CBDV, CBG, CBD, THCV, CBN, Δ8THC and Δ9THC were matched using retention time 
and MS/MS analysis (Figure 4.2), correlated with the relevant individual standards. A peak 
for CBC was not detected. 2 of the 3 cannabinoids present in the acidic mixed standard 
produced peaks, retention time and MS/MS matched to CBDA and CBGA. When the two 
Figure 4.1: LC/MS/MS chromatogram of a 1 µL injection of a mixed cannabinoid 
standard containing 11 cannabinoids. 
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mixed standards were injected together, 7 peaks were present, with retention time and 
MS/MS used to match 10 of the 11 cannabinoids (Figure 4.3). CBC was again not detected in 
the mixed standard, but eluted at 12 min when injected individually. Co-elution occurred 
between THCA and Δ9THC; and CBG and CBGA. Many peaks had visible shoulders. The 





































Figure 4.2a: LC/MS/MS mass spectra for 11 cannabinoids. MS and MS2 are the top 
and bottom spectra respectively for each cannabinoid. Full scan chromatograms for 
MS utilising retention time and molecular weight extracted ion chromatograms are 
present for MS2. Figure continued on next page. 





















Figure 4.2b: LC/MS/MS mass spectra for 11 cannabinoids. MS and MS2 are the top 
and bottom spectra respectively for each cannabinoid. 















The third aim for this project was to get an indication of the potential of LC/MS/MS for 
cannabinoid analysis, using the optimised LC/PDA method as a starting point. 1 µl injections 
failed to produce peaks, but did indicate that the LoD for this technique is higher than that of 
the standards, with the most concentrated standard being 0.1 mg/mL. This LoD is 
significantly higher than was determined for GC/MS and LC/PDA and should be investigated 
further. Sensitivity could be increased by various approaches to method optimisation, but the 
data obtained does suggest a possible reason why LC/MS has not been popular for 
cannabinoid analysis.  
Figure 4.3: LC/MS/MS chromatogram of a 20 µL injection of a mixed 
cannabinoid standard containing 11 cannabinoids. 10 cannabinoids were 
matched in the mixed standard chromatogram, with no peak detected for CBC. 
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20 µl injections indicated that the cannabinoids were capable of being detected by 
LC/MS/MS, however the use of a 20 µl injection volume is not ideal because of the 
possibility of overloading the detector and the need for a larger sample size. The minimum 
and maximum concentrations injected at 20 µl were 0.12 and 2 mg/mL respectively, and the 
peaks between 0.24 and 2 mg/mL reached the maximum abundance. The maximum that the 
MS/MS detector can detect is reached when the concentration of an injection is high enough 
to saturate the detector, this becomes an issue when the ion ratios become altered due to 
multiple ions reaching this maximum. Regardless of concentration, all of the 
chromatographic peaks exhibited abnormal peak shape and shouldering, which could be due 
to the high injection volume used and the ratio of acetonitrile to water in the MS system. 
Further development of the method is required to improve the peak shapes and more 
precisely determine the LoD. 
Other aspects of the method will also require further optimisation. The baseline has a lot of 
noise and is on an incline, indicating that the gradient and buffer may need evaluation. This 
will affect separation of the cannabinoids which also needs to be optimised. Instances of co-
elution could be explored using the MS/MS function, however physical separation would be 
preferred. The cannabinoids that were not detected in the mixed standard are particularly 
problematic. In the case of CBC, this absence could be explained by the baseline and noise at 
the expected retention time of 12 min, causing the peak for CBC to be hidden in the noise. 
However, the molecular weight ion was unable to be extracted to produce a spectra indicating 
that a bigger problem is present and requires more exploration. 
4.4 Conclusions 
The optimisation carried out for the LC/MS/MS method was limited, however it did at least 
provide a good starting point for further methods development. While this was initially 
-  7 7  -  |  P a g e  
 
considered beyond the scope of the project, the data suggests that LC/MS/MS could combine 
the best of both GC/MS and LC/PDA, in terms of identification and separation capabilities. 
The use of a ‘soft’ technique such as LC for separation will reduce or eliminate the potential 
breakdown of cannabinoids through the separation process. The MS detector allows 
qualitative identification based on ionisation patterns making it more discriminatory than UV, 
although the use of electrospray ionisation does involve relatively harsh conditions, such as 
the evaporation of volatile solvents. The additional capability provided by MS/MS may allow 
the separation of co-eluting compounds based on molecular weight or base peak ions, as an 
additional discriminatory factor. These capabilities were not investigated due to time 
constraints and warrant further investigation, as does the sensitivity of the method, which 
currently represents a limitation to the use of LC/MS/MS for this analysis. Overall, the data is 
promising, but substantial optimisation is necessary to fully develop a method for the analysis 
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CHAPTER 5: Sample results for LC/PDA  
LC/PDA analysis was chosen as the preferred method for the quantitation of cannabinoids. 
This decision was based partly on availability of the instrument, as well as the extensive 
literature utilising this approach. LC/PDA was chosen over GC/MS because it is a ‘softer’ 
technique, in terms of separation and detection. 
5.1 Sample preparation 
The chromatographic results were similar using all three solvents, acetonitrile, ethanol and 
methanol. However, there were differences in the retention times (Figure 5.1), most likely 
due to instrument variability. This data was acquired prior to instrument maintenance and due 
to the observed retention time shifts, only the acidic cannabinoids could be quantified. THCA 
and CBDA quantitative results were similar across all solvents with relative standard 










Figure 5.1: LC/PDA chromatograms of the control sample using 3 solvents: 
acetonitrile, ethanol and methanol, measured at 270 nm. The peaks correspond with 
CBDA and THCA from left to right, retention time shift was due to a mechanical 
problem. 
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Table 5.1: Quantitative results for THCA and CBDA for a control plant material sample 
extracted in three solvents: acetonitrile, ethanol and methanol using LC/PDA. Values are 
averages of duplicate. 
 Solvent  
Cannabinoid Acetonitrile Ethanol Methanol %RSD 
THCA (%) 0.29 0.30 0.30 1.94 
CBDA (%) 0.67 0.66 0.74 6.31 
 
5.2 Validation  
5.2.1 Linearity and Sensitivity 
The calibration curves for each compound were linear (Appendix 3), with correlation 
coefficients indicating very strong positive slopes (Table 3.8). 
The sensitivity of the instrument was determined via the slope of the curve, which was 
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Table 5.2: Slope and y-intercept for 11 cannabinoid calibration curves, measured at 228 and 
270 nm. 
 
 228 nm 270 nm 
Cannabinoid Slope y-intercept Slope y-intercept 
CBDV 3350.2 -0.31 194.0 -0.03 
CBDA 3748.8 6.44 1306.3 0.84 
CBGA 4457.8 5.86 1460.4 1.03 
CBD 2963.7 0.38 177.3 0.37 
CBG 2984.9 2.15 126.2 0.33 
THCV 2783.1 2.93 129.8 0.19 
CBN 5786.8 1.39 1493.1 -0.08 
Δ9THC 3413.6 2.27 182.5 0.02 
Δ8THC 2723.3 -3.39 185.3 0.04 
CBC 5616.0 -0.43 821.1 0.44 
THCA 3643.8 5.74 1691.0 -0.35 
 
5.2.2 Precision 
Precision data includes reproducibility and repeatability.  
5.2.2.1 Control data and repeatability 
The calibration curves were used to determine total THC content (%) in duplicate (Table 5.3), 
using the known equation18: 
[Active Δ9THC] = [Δ9THC] + 0.877 [Δ9THCA] 
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Table 5.3: Total active Δ9THC content in a control sample determined using LC/PDA. Values 
are averages of duplicate. 
 %THCA % Δ9THC Active Δ9THC (%) 
Mean 0.29 0.13 0.38 
SD 0.007 0.004 0.010 
%RSD 2.37 3.08 1.75 
 
CBDV, CBGA, CBG, CBN, Δ8THC, CBC (Table 5.4), CBDA, THCA (Table 5.1) and 
Δ9THC (Table 5.4) were all detected in the hemp control and experimentally determined. 
Other peaks were also present but not allocated to a known compound.  
Table 5.4: Cannabinoid quantitation data from LC/PDA analysis of the hemp control, except 
for THCA and Δ9THC which is summarised in Table 5.3. N/A refers to cannabinoids that 
were not able to be quantified as they were below the LoQ; <LoQ refers to a cannabinoid that 
was only quantified in singlet due to the duplicate being below the LoQ. 
Compound Mean (%) SD %RSD 
CBDV Below LoQ N/A N/A 
CBDA 0.745 0.007 0.94 
CBGA Below LoQ N/A N/A 
CBG 0.215 0.007 3.26 
CBN 0.034 0.004 11.8 
Δ8THC Below LoQ N/A N/A 
CBC 0.03 <LoQ <LoQ 
 
5.2.2.2 Reproducibility 
Reproducibility was investigated using the area counts for each cannabinoid at each injection 
level. The RSD value was used as an indication on the relative distance of the duplicates from 
the mean; values ranged from 0.37 to 30.2% (Appendix 4).  
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5.3 Sample Analysis 
Sample analysis was attempted to view the effectiveness of the single-step extraction 
procedure and to gain insight into the approximate dilutions needed for various products. 
Two types of samples were analysed: low THC plant material and oil from the Chemcentre, 
WA police and various anonymous hemp producers. Both were weighed and extracted in 
singlet using the procedure outlined in section 3.6.1.3. 
5.3.1 Oil  
Oil samples required a larger dilution to fit in the calibration curve. 5-fold diluted samples 
were above the calibration curve by approximately 30-fold and produced split and broadened 











 Figure 5.2: LC/PDA chromatograms of Cannabis oil sample 1 at a 5-fold (top) and 
50-fold (bottom) dilution, measured at 270 nm. 
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Eight oil samples were run in singlet and indicated varying cannabinoid compositions (Table 
5.5), with multiple peaks unable to be identified. The most abundant cannabinoid was CBG 
followed by CBDA. The least abundant cannabinoid was CBGA, which was not detected in 
any of the samples. Oil sample 2 was analysed prior to instrument maintenance and so only 
acidic cannabinoids were able to be quantified. 
Table 5.5: Cannabinoid composition of 8 oil samples using LC/PDA, in singlet, and sum of 
the individual cannabinoids in the 7 samples. N/A refers to cannabinoids that weren’t 
detected in the sample; <LoQ refers to cannabinoids that fell below the limit of quantitation. 
– in sample 2 refer to the neutral cannabinoids that were unable to be quantified at that point. 
























































1 0.24 6.63 N/A 0.13 12.30 N/A 0.12 0.69 <LoQ 0.58 0.08 
2 - 1.16 0.54 - - - - - - - 0.13 
3 0.20 5.42 N/A 0.10 9.93 <LoQ 0.16 0.75 <LoQ 0.47 0.07 
4 0.23 9.47 N/A 0.18 11.98 <LoQ 0.19 0.68 <LoQ 0.56 0.07 
5 0.21 5.74 N/A 0.11 10.59 <LoQ 0.13 0.79 <LoQ 0.50 0.07 
6 0.31 8.34 N/A 0.17 15.57 <LoQ 0.24 0.86 <LoQ 0.73 0.10 
7 0.35 9.29 N/A 0.19 17.30 <LoQ 0.19 0.97 0.21 0.82 0.11 
8 0.19 5.23 N/A 0.14 9.66 N/A 0.14 0.71 <LoQ 0.45 0.06 
Total  1.73 50.12 N/A 1.02 87.33 <LoQ 1.17 5.45 0.21 4.11 0.56 
 
5.3.2 Plant material  
The concentration of the plant material samples varied greatly both between samples, and 
between individual cannabinoids (Figure 5.3). The samples were provided as hemp, illicit 
samples were not able to be analysed due to time constraints. Most cannabinoids and samples 
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were within the calibration range at 5-fold dilutions, with CBDA and CBN being the only 
cannabinoids with area counts above the calibration curve and requiring further dilution. 
Some samples indicated Δ9THC levels below the LoQ. The hemp samples contained a variety 
of different cannabinoids (Table 5.6), identified based on retention time and UV spectra. The 
plant material samples sample results varied, with the THC content mostly being under that 















Figure 5.3: LC/PDA chromatograms of plant materials samples 1, 2 and 3 indicating 
the variety of cannabinoid compositions. The top and bottom chromatograms for each 
sample are using wavelengths 270 and 228 nm respectively. 
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10 plant material samples were unfortunately run in singlet and tentatively indicated varying 
cannabinoid compositions (Table 5.6), with multiple peaks unable to be identified. The most 
abundant cannabinoid was CBDA, while the least abundant was CBC. 
Table 5.6: Cannabinoid composition of 10 plant material samples using LC/PDA, in singlet, 
and sum of the individual cannabinoids in the 7 samples. N/A refers to cannabinoids that 
were not detected in the sample; <LoQ refers to cannabinoids that fell below the limit of 
quantitation. 

























































1 <LoQ 0.18 <LoQ <LoQ 0.06 0.08 0.11 0.06 0.07 <LoQ 0.10 
2 <LoQ 0.22 <LoQ <LoQ 0.08 N/A 0.02 N/A 0.16 0.01 0.04 
3 <LoQ 0.12 N/A N/A 0.06 N/A <LoQ <LoQ <LoQ <LoQ <LoQ 
4 0.01 0.26 N/A N/A <LoQ 0.21 0.02 0.04 0.08 <LoQ 0.02 
5 0.01 0.42 0.01 <LoQ 0.25 0.02 0.03 0.08 0.14 0.03 0.07 
6 <LoQ 0.16 <LoQ <LoQ N/A 0.04 <LoQ <LoQ <LoQ <LoQ <LoQ 
7 0.09 <LoQ 0.45 0.17 <LoQ N/A <LoQ <LoQ N/A <LoQ <LoQ 
8 0.03 0.02 <LoQ <LoQ 0.22 N/A 0.01 0.04 0.01 0.01 <LoQ 
9 0.03 0.15 0.01 N/A 0.02 0.25 0.18 N/A 0.32 <LoQ 0.20 
10 <LoQ 0.02 N/A N/A 0.07 N/A <LoQ <LoQ N/A <LoQ <LoQ 
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CHAPTER 6: Discussion for LC/PDA sample results 
This study tested the suitability of three analytical platforms for analysis of cannabinoids. The 
chromatographic techniques used were GC and LC, and each presented its own advantages 
and disadvantages. Three detectors were investigated: MS, PDA and MS/MS, and each 
provided different types and degrees of information on the target cannabinoids. Each 
combination of separation and detection was able to separate some or all of the 11 target 
cannabinoids. GC/MS could not be applied to acidic cannabinoids, without modification or 
additional steps, due to their decarboxylation and subsequent transformation into neutral 
cannabinoids. LC/PDA was chosen as the platform to analyse samples, as this technique was 
the most developed and could successfully quantify all 11 target cannabinoids. The method 
was not fully validated, but is on track for full validation. 
6.1 Sample preparation 
The extraction processes tested were limited by time and instrument availability. Methanol, 
ethanol and acetonitrile were trialled due to their availability, cost and presence in the 
primary standards and/or solvent system. These three solvents are compatible with reverse 
phase LC due to their more polar nature, in contrast to the non-polar stationary phase. They 
are also relatively inert. Organic solvents especially alcohols have been shown to be optimal 
for cannabinoid extraction due to their polar natures and ability to penetrate plant material to 
dissolve and extract cannabinoids74. The findings of this project align with this conclusion. 
Concentration data for each solvent indicated that they are equivalent in terms of extraction 
efficiency. RSD values between solvents were below 10% which is comparable to historical 
data (Table 5.1). Extraction with any of the three solvents would be fit for purpose and 
appropriately reproducible. 
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The acidic and neutral primary standards were dissolved in acetonitrile and methanol, 
respectively. This is likely due to possible esterification of the organic acids in an alcohol 
solvent, however acidic cannabinoid standards in methanol are available from other suppliers 
indicating this isn’t a major problem. For this part of the study, only acidic cannabinoids were 
able to be measured, so a different response may be observed if this were repeated with 
neutral cannabinoids. Ethanol was used for the following extractions due to its neutrality, cost 
and effectiveness, and if there is a solvent-based difference in response of the two groups, it 
would be expected to be similar to methanol. 
Further experimentation should be carried out with the final method to determine if the 
response of neutral cannabinoids is affected by the different solvents. Multi-step extraction 
should also be investigated, coupled with the use of an internal standard, such as prazepam, to 
monitor extraction and retention efficiency through this process. A general multi-step 
extraction would use ethanol as the initial extraction solvent, followed by N2 evaporation of 
the sample and reconstitution in any of the solvents listed. In the case of oils, a filter could be 
used to remove particulates, followed by the N2 stream and reconstitution
21,22. This could 
provide a more accurate result and accounts for extraction inefficiencies using an internal 
standard such as prazepam as discussed in the method development for LC/PDA. To 
accurately assess the effectiveness of different extraction methods, a reliable and validated 
analytical method needs to be available to quantitatively evaluate the sample preparation 
process. 
6.2 Validation 
The validation of an analytical method is essential to demonstrate the reproducibility and 
transferability of the method. All data available for this project was in duplicate and thus is 
insufficient to validate the method, with data suggesting further optimisation is required.  
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6.2.1 Linearity and sensitivity 
The linearity and sensitivity of the method are related to the calibration curves, which were 
consistently linear (Appendix 3) with a high correlation coefficient (Table 3.8). Good 
linearity is indicative of a method that will be successful for quantitative analysis and 
indicates stability of the compound and instrument across the concentration range. 
Additionally, the y-intercepts (Table 4.2) were close to zero, demonstrating that the linearity 
of the slope for LC/PDA could extend to lower concentrations if extrapolated. 
Furthermore, the slopes of each line were relatively high (Table 4.2). The greater the slope 
the greater the sensitivity of the method, and thus minor changes in concentrations could be 
monitored. A detection wavelength of 228 nm was more sensitive due to the slope being 
larger than for 270 nm. This may be counter acted by the sloped baseline and higher LoQ for 
228nm, making lower concentrations difficult to quantify without extrapolation, despite 
detecting concentration changes more easily. 
6.2.2 Precision  
6.2.2.1 Control data and repeatability 
Repeatability can be calculated using a control sample of known amount of target compound.  
A control is often necessary to monitor each run of a single method for variation. Incidents 
such as pressure changes, inconsistent gradients, abnormal integration or ineffective dilution 
should be visible if the control does not fall within a defined limit, triggering further 
investigation of method parameters. Control data should ideally be within one standard 
deviation of the sample mean to indicate a high level of repeatability and consistency, this 
can be confirmed through validation statistics with multiple injections of the control. 
The hemp control detailed in section 5.2 was intended to be used as a vehicle to indicate the 
repeatability of the method. The control data could only be analysed in duplicate and did 
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indicate a level of repeatability, but further control results are required to provide a greater 
confidence and a more accurate mean and standard deviation.  Based on the duplicate data the 
method appears to be repeatable for Δ9THC, THCA, CBDA and CBG with RSD values less 
than 4% (Tables 5.3 and 5.4). The RSD was above 10% for CBN (Table 5.4), signifying that 
the quantification for CBN was not sufficiently repeatable. It was difficult to produce control 
data for all 11 target cannabinoids, as they were not all present in the control sample. 
Additionally, the high RSD for one cannabinoid reduces confidence in the repeatability of the 
other cannabinoids. An important limitation to this project was the limited data generated, 
more data will allow appropriate statistical analysis to be applied to validate the method for 
commercial use.  
Some historical data was available for the Δ9THC content of the control. Comparison of the 
Δ9THC historical data determined using GC/MS to this project’s data derived from LC/PDA 
provided some useful information into the accuracy of the method being developed. The 
calibration curves produced in this study were used to determine the total THC content using 
LC/PDA and compared to a historically used hemp control with a known amount of THC 
(Table 6.1). Historically, the control had only been analysed for THC content. CBDA, 
CBDV, CBGA, CBG, CBN, Δ8THC, Δ9THC, CBC and THCA (Tables 5.3 and 5.4) were 
also found in the hemp control and experimentally determined with no comparison to 
historical data. Other peaks were also present, but were not identified to a known compound. 
The data was in duplicate due time constraints, whereas the historical data used > 20 
replicates. The Δ9THC content measured using GC/MS was 0.30%, which is almost 25% less 
than the LC/PDA results of 0.38%. 
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Table 6.1: Comparison of active Δ9THC content in a control sample determined in this study 
using LC/PDA to historical data using GC/MS. 
 Historical hemp control 
data (GC/MS)75 (% w/w) 
Experimental control data (% w/w) 
% Δ9THC Active Δ9THC Δ9THC THCA 
Mean 0.30 0.38 0.13 0.295 
SD 0.05 0.010 0.004 0.007 
%RSD 6.67 1.75 3.08 2.37 
 
GC/MS and LC/PDA data may not be directly comparable because of the rate of 
decarboxylation of each molecule of THCA in the GC/MS2,60,62. Differences would cause the 
concentration Δ9THC to fluctuate for each injection, and therefore not reflect the full 
conversion of THCA. This may be apparent in the approximately 10-fold high standard 
deviation of the GC/MS result compared to the LC/PDA results. Another alternative 
explanation for the higher standard deviation may simply be the number of replicates 
compared to the duplicates of LC/PDA. The RSD for all data was below 10% and fit-for-
purpose. The RSD for the LC/PDA results was below 5%, indicating a greater repeatability.  
6.2.2.2 Reproducibility  
Reproducibility calculations used duplicates of the area counts for each cannabinoid at each 
sample injection, and the RSD were indicative of the spread of the data. As the data is in 
duplicate, it is subject to further replication and statistical analysis to fully establish the 
reproducibility of the method. The current data indicates that the method was not 
reproducible, as most of the injections had a RSD greater than 10%. This value indicates that 
there was a greater dispersion between data points (due to two data points being used this is 
expected) thus a low probability of the area counts of subsequent runs reflecting the mean 
value. Increased sample sizes, in this case replicates, could decrease this value and identify 
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any outliers that may be present in the data. Outliers are a probability for this data, due to the 
HPLC pressure variability observed during the end of the analytical batch. The data was 
included in the final analysis to enable some tentative statistical analysis.  
6.2.3 Validity 
Ideally, at the conclusion of method validation, a measurement uncertainty is determined 
from the precision data to give an overall indication of the dispersion of any measured value, 
such as concentration or dilution. This has not been calculated here due to the lack of data 
and the limits to reproducibility. In future, a measurement uncertainty value should be 
evaluated, with a value +/- 10% or 1 standard deviation ideal for a commercial application. 
The limited statistics have not validated the method, therefore aim 2.1 has not yet been 
completed, and are a limitation of the work accomplished by the project. 
6.3 Sample analysis 
The analysis of several types of samples was aim 2.2 of this project. The goal was to produce 
a method that could quantitate cannabinoids in various forms such as oil, butter and plant 
material. Due to time constraints, only two types of samples were attempted: oil and plant 
material (low Δ9THC), which was indicated to contain low Δ9THC concentration (<0.3% 
w/w). The data available was not only limited by form but also sample size, extraction 
methods and instrumental variability. A single step extraction method, as suggested in the 
introduction, was not sufficient for all forms of sample. The data in this section should also 
be taken as preliminary and pending further analysis to fully validate the final LC/PDA 
method. 
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6.3.1 Oil  
Oil presents a unique and difficult matrix, as it contains many biological compounds, 
including cannabinoids, which may affect the extraction and separation of the target analytes 
Chromatograms for the oil samples indicated many peaks, some of which were identified as 
cannabinoids via their UV spectra, while others were unable to be identified, which may be 
plant-derived compounds such as terpenes. Ideally, the extraction process would target only 
cannabinoids, and as such the chromatogram would be much cleaner, however this did not 
occur and requires further development of a targeted extraction process. However, a method 
which could extract both cannabinoids and terpenes could lead to the simultaneous analysis 
of these compounds of interest. While beyond the scope of this project, it is possible that this 
may be of interest to industry in the future. 
Potential limitations of the single step extraction process were highlighted by comparison of 
the acidic cannabinoid data from oil sample 2 using the LC/PDA to the brochure results76 
provided with the sample (Table 6.2). The source of information is questionable, however it 
does provide an example of a product marketed as medicinal Cannabis that may not have 
accurate information on cannabinoid composition.  Oil sample 2 was found to contain 
approximately the same amount of CBGA, more THCA and less CBDA than the brochure 
indicated. This may be due to single step extraction inefficiencies, however the Endoca report 
201676 indicated a similar extraction method using only methanol. 
The other seven oil samples analysed did not have previous results for comparison. Sample 
size is limited, so further investigation and comparison is required. Use of an internal 
standard such as prazepam along with a multi-step extraction process would be necessary for 
further analysis as discussed in section 6.1.  
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Table 6.2: Comparison of cannabinoid composition in a ‘medicinal Cannabis CBD oil’ 
determined in this study using LC/PDA to the accompanying report76. – indicates a 
cannabinoid that was unable to be quantified. 
Cannabinoid Brochure76 (% w/w) 
LC/PDA (section 5.3.1) 
(%w/w) 
THC <0.10 - 
THCA <0.10 0.13 
CBD 16.55 - 
CBDA 4.57 1.16 
CBG <0.10 - 
CBGA 0.52 0.54 
CBN 0.13 - 
 
6.3.2 Plant material  
Plant material was the second form of Cannabis analysed in this project to meet the diversity 
of forms specific in aim 2.2. The samples were previously dried and ground, which is 
necessary to eliminate water from the sample and ensure that the total weight used, for the 
%w/w calculation, is consistent and not affected by water absorption2,4,5,18,57. As with the oil 
samples, extraction for the plant material samples was a single step using ethanol. Dilutions 
to fit within the calibration curve varied based on the initial concentration of the 
cannabinoids. For most samples, a 5-fold dilution was sufficient, likely due to the lower THC 
content in hemp samples. 
Some of the hemp samples could be compared to their analysis via the validated GC/MS 
method75 mentioned previously, undertaken by the ChemCentre using their standard and 
validated hemp procedure for quantification of Δ9THC (Table 6.3). The results were different 
for each technique, however this study was undertaken between 4 - 10 years after the original 
analysis so comparison is limited. Differences can likely be accounted for by degradation of 
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the cannabinoid21,40,43,57, leading to the lower levels measured in this analysis. Samples with 
higher concentrations in the previous GC/MS analysis also produce higher values in this 
LC/PDA analysis, so there is a degree of comparison. 
Table 6.3: Comparison of active Δ9THC content determined in this study using LC/PDA to 
previous data generated using GC/MS.  
  Active Δ9THC (%w/w) 
Plant material 
sample 
Year of sample 
submission 
GC/MS75 LC/PDA 
1 2009 0.24 0.15 
2 2010 0.24 0.04 
3 2009 0.09 0 
4 2010 0.23 0.06 
5 2010 0.54 0.14 
6 2007 0.09 0 
7 2010 <0.05 0 
8 2013 0.15 0.04 
9 2009 0.35 0.18 
10 2013 <0.05 0 
 
As this projects data was in singlet, further replicates should be analysed for a more accurate 
comparison. The results are promising and align with other research, suggesting that 
cannabinoids degrade over time and that LC/PDA can be an appropriate technique for 
cannabinoid analysis in plant material. As observed with the oil samples, peaks not matched 
to the 11 cannabinoids in this project were present and further cannabinoids and compounds 
could be added to the method in the future. 
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6.4 Techniques for cannabinoid analysis 
A major aim in this experiment was to manipulate instrumental conditions to produce robust 
data, which provided an insight into the effects on the resulting data. The ability to separate 
all 11 target cannabinoids in a quantifiable way has produced a method that could with 
further validation be at least equivalent to previous research in terms of commercial value to 
the State of WA, quality guidelines and the number of cannabinoids analysed. The method 
will hopefully provide a way to analyse future medicinal/other cannabis products in the ever-
growing industry. Additionally, the methods were constructed in WA and will attempt in the 
future and via validation to conform to local legal guidelines for the analysis of cannabis 
products. To further this research components of cannabis such as terpenes and heavy metals 
could be analysed to provide a more complete profile of this complex plant system. 
GC/MS is an excellent technique for the analysis of cannabinoids, having been used for 
decades. The method has limitations, while it allows qualitative analysis of neutral 
cannabinoids, quantitative analysis can only be achieved for select cannabinoids at a limited 
range. This includes cumulative concentrations of the acidic cannabinoids, although 
derivatisation would provide a solution to decarboxylation of the acidic cannabinoids, 
allowing acidic and neutral cannabinoids to be quantified as separate compounds. However, 
the unexplained degradation and/or break down of cannabinoids such as CBG and CBC will 
prevent them being quantified by this method. LoQ values for both GC/MS and LC/PDA 
were similar indicating both will work for the same concentration samples. LC/MSdoes not 
use high temperatures and as such may not degrade or alter the chemical structure of the 
cannabinoids, and the method is substantially faster, and thus preferred in a commercial 
setting. 
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LC/PDA was successful in separating all 11 target cannabinoids. The use of two different 
detection wavelengths allowed the acidic and neutral cannabinoids to be detected and an 
optimal wavelength chosen for the calibration and quantitation of the sample. This method is 
preferred over GC/MS for quantitative evaluation due to its ‘softer’ conditions (e.g. 
temperature), although it is limited in its ability to identify the cannabinoids using a 
discriminatory feature other than retention time. It was useful to successfully separate 11 
cannabinoids and create calibration curves for each, allowing efficient quantitative analysis of 
cannabinoid content. Without validation, this data is to be considered preliminary, with the 
intention to complete validation and fully document the capabilities of the method. 
As this study was being completed an article was published in by Wang et al.77 separating 
and quantifying 11 and 9 cannabinoids respectively in Cannabis and Cannabis products using 
Ultra-High-Performance Supercritical Fluid Chromatography and Photodiode Array/Mass 
Spectrometric Detection (UHPSFC/PDA-MS). This article addressed some of the aspects of 
cannabinoid analysis that were lacking, such as the number of cannabinoids separated in a 
single method and the analysis of non-plant Cannabis material items, which were the broader 
aims of this project. The two studies are similar and comparable, aiming towards more 
intense and varied Cannabis research than standard THC analysis in plant material. Both 
studies look at instrumental methods different to GC/MS that do not require or cause 
cannabinoid transformation through derivatisation or decarboxylation. UHPSFC/PDA-MS 
also provides the ability to discriminate cannabinoids in complex mixtures77. This may be 
possible via LC/MS/MS, however if a PDA/MS system becomes available, it would be a 
worthwhile investigation, as Wang et al.77 has promising data and valuable validation 
statistics.  
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6.5 Conclusion 
The emerging use of cannabis as a legitimate and legalised form of medication for a range of 
illnesses/diseases is producing a need for current, efficient and commercially viable and 
available scientific methods for the analysis of the contents of Cannabis plant material and 
derived products such as medicines. An ideal method would have the ability to qualitatively 
and quantitatively determine all compounds within the products. However, as cannabinoids 
are the major medicinally valuable constituents of Cannabis, they are the focus of 
considerable research. Current methods in WA are single cannabinoid focused, and do not 
have the ability to separate a number of cannabinoids, this restricts the ability to quantify a lot 
of the cannabinoids now the focus of medical research. A commercial and validated method 
for WA is a project worth investigating. 
The broad aim of this project was to develop an understanding of instrument condition 
manipulation to allow development of a LC/PDA method that could separate 11 of the most 
prevalent cannabinoids. Further to this, an aim was to validate this method for commercial 
use, with efficient use of time and materials. The LC/PDA method successfully separated 11 
cannabinoids selected, allowing quantification of each cannabinoid. The method could be fit-
for-purpose and meets core commercial needs. A lateral aim was to evaluate the scope of the 
project in terms of the ability to analyse Cannabis in various forms such as plant material and 
oils. Further research is needed to develop the method for other Cannabis products and to add 
more cannabinoids, however based on preliminary results, medicinal products such as oil can 
be analysed, particularly with further development of the extraction process and validation of 
the method. Due to time and instrument constraints, the validation of the LC/PDA method of 
this project was incomplete, however valuable information was gained with respect to 
manipulation of instrument conditions and the potential of the method with further replication 
and statistical analysis.  
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The future for cannabinoid analysis is vast, and this project has only scratched the surface of 
the possibilities. It examined three techniques that may be used simultaneously or in isolation 
to better profile Cannabis products and provide information on their contents. Research into 
Cannabis involves many disciplines and these analytical techniques could provide crucial 
information to areas such as the medicinal effects of the rarer cannabinoids such as CBDV. If 
terpenes were to be added to the method, dissecting the biological interactions of the different 
compounds in Cannabis may aid in understanding synergistic mechanisms. GC/MS, 
LC/MS/MS and/or LC/PDA are powerful tools in Cannabis analysis and furthering 
individual and mass/commercial knowledge of the topic to prepare for the future needs of 
industry and regulatory bodies. 
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Appendix 2: GC/MS full curves  
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Appendix 4: LC/PDA raw data of duplicate area counts for various standard injections at 
different concentrations of all 11 cannabinoids. 
CBDV Area 270nm  Area 228nm  
Concentrations 1 2 AVG Std Dev RSD% 1 2 AVG Std 
Dev 
RSD% 
0.003 0.52 0.57 0.545 0.025 4.587156 N/A N/A N/A N/A N/A 
0.006 1.07 1.48 1.275 0.205 16.07843 22.01  22.01 0 0 
0.012 1.9 2.77 2.335 0.435 18.62955 32.2 45.24 38.72 6.52 16.83884 
0.024 3.78 5.59 4.685 0.905 19.31697 65.07 94.39 79.73 14.66 18.38706 
0.036 5.63 8.4 7.015 1.385 19.74341 97.9 140.5 119.2 21.3 17.86913 
0.048 7.32 10.47 8.895 1.575 17.70658 132.73 189.45 161.09 28.36 17.60507 
0.06 9.47 13.57 11.52 2.05 17.79514 162 236.93 199.465 37.465 18.78274 
0.09 14.28 21.05 17.665 3.385 19.16219 246.63 357.89 302.26 55.63 18.40468 
0.12 18.76  18.76   330.33     
 
CBGA Area 270nm   Area 228nm   
Concentrations 1 2 AVG Std Dev RSD% 1 2 AVG Std Dev RSD% 
0.003 9.48 
 
N/A N/A N/A 32.31 
 
N/A N/A N/A 
0.0075 10.83 10.91 10.87 0.04 0.367985 56.51 
 
N/A N/A N/A 
0.015 21.14 23.13 22.135 0.995 4.495143 62.04 78.34 70.19 8.15 11.61134 
0.03 41.75 45.16 43.455 1.705 3.923599 104.48 153.3 128.89 24.41 18.93863 
0.06 83.53 92.8 88.165 4.635 5.257188 224.88 315.88 270.38 45.5 16.82817 
0.09 125.68 138.07 131.875 6.195 4.69763 338.56 470.43 404.495 65.935 16.30057 
0.12 167.21 185.01 176.11 8.9 5.05366 450.59 629.16 539.875 89.285 16.53809 
0.15 207.46 231.65 219.555 12.095 5.50887 556.05 787.71 671.88 115.83 17.23969 
0.225 312.89 348.44 330.665 17.775 5.375531 863.19 1164.69 1013.94 150.75 14.86774 
0.3 407.6 
 
407.6 N/A N/A 1169.24 
 
1169.24 N/A N/A 
 
CBDA Area 270nm  Area 228nm  
Concentrations 1 2 AVG Std Dev RSD% 1 2 AVG Std Dev RSD% 
0.003 
 
7.68 7.68 N/A N/A N/A N/A N/A N/A N/A 
0.0075 10.91 8.44 9.675 1.235 12.76486 
 
49.89 49.89 N/A N/A 
0.015 23.13 16.48 19.805 3.325 16.78869 66.66 51.76 59.21 7.45 12.58233 
0.03 45.16 32.69 38.925 6.235 16.01798 129.81 99.58 114.695 15.115 13.17843 
0.06 92.8 65.15 78.975 13.825 17.50554 266.65 188.14 227.395 39.255 17.26291 
0.09 138.07 97.93 118 20.07 17.00847 396.12 283.2 339.66 56.46 16.6225 
0.12 185.01 130.56 157.785 27.225 17.25449 530.13 377.52 453.825 76.305 16.81375 
0.15 231.65 161.71 196.68 34.97 17.78015 663.07 466.31 564.69 98.38 17.42195 
0.225 348.44 241.9 295.17 53.27 18.04723 988.8 725.13 856.965 131.835 15.38394 
0.3 
 
338.14 338.14 N/A N/A 
 
985.41 985.41 N/A N/A 
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CBD Area 270nm   Area 228nm   
Concentrations 1 2 AVG Std Dev RSD% 1 2 AVG Std Dev RSD% 
0.003 0.45 0.41 0.43 0.02 4.651163 
  
N/A N/A N/A 
0.006 0.93 1.44 1.185 0.255 21.51899 19.18 
 
N/A N/A N/A 
0.012 1.82 2.9 2.36 0.54 22.88136 35.88 39.76 37.82 1.94 5.129561 
0.024 3.64 6.07 4.855 1.215 25.02575 60.99 81.86 71.425 10.435 14.60973 
0.036 5.4 8.86 7.13 1.73 24.26367 91.47 121.5 106.485 15.015 14.10058 
0.048 7.22 11.89 9.555 2.335 24.43747 121.14 161.73 141.435 20.295 14.34935 
0.06 8.36 14.26 11.31 2.95 26.08311 146.17 200.72 173.445 27.275 15.72545 
0.09 11.04 20.16 15.6 4.56 29.23077 263.35 278.41 270.88 7.53 2.779829 
0.12 18.12 
 
N/A N/A N/A 327.71 
 
N/A N/A N/A 
 
CBG Area 270nm   Area 228nm   
Concentrations 1 2 AVG Std Dev RSD% 1 2 AVG Std Dev RSD% 
0.003 0.37 0.54 0.455 0.085 18.68132 
  
N/A N/A N/A 
0.006 0.68 1.02 0.85 0.17 20 23.46 
 
N/A N/A N/A 
0.012 1.34 2 1.67 0.33 19.76048 36.26 42.03 39.145 2.885 7.370034 
0.024 2.66 4.17 3.415 0.755 22.10835 58.12 86.99 72.555 14.435 19.89525 
0.036 4.02 6.18 5.1 1.08 21.17647 86.81 129.55 108.18 21.37 19.75411 
0.048 5.26 8.3 6.78 1.52 22.41888 114.57 172.5 143.535 28.965 20.17975 
0.06 6.29 10.3 8.295 2.005 24.17119 138.98 214.12 176.55 37.57 21.28009 
0.09 8.92 14.4 11.66 2.74 23.49914 249.44 301.43 275.435 25.995 9.437798 
0.12 15.1 
 
N/A N/A N/A 330.79 
 
N/A N/A N/A 
 
THCV Area 270nm   Area 228nm   
Concentrations 1 2 AVG Std Dev RSD% 1 2 AVG Std Dev RSD% 
0.003 0.38 0.67 0.525 0.145 27.61905 
  
N/A N/A N/A 
0.006 0.71 1.01 0.86 0.15 17.44186 
 
23.43 N/A N/A N/A 
0.012 1.34 1.99 1.665 0.325 19.51952 42.03 34.89 38.46 3.57 9.282371 
0.024 2.6 4.1 3.35 0.75 22.38806 80.09 53.8 66.945 13.145 19.63552 
0.036 3.95 6.02 4.985 1.035 20.76229 120.59 81.08 100.835 19.755 19.59141 
0.048 5.15 8.02 6.585 1.435 21.79195 161.5 107.35 134.425 27.075 20.14134 
0.06 6.27 10.03 8.15 1.88 23.06748 201.31 132.46 166.885 34.425 20.62798 
0.09 8.93 14.34 11.635 2.705 23.24882 292.46 222.86 257.66 34.8 13.50617 
0.12 11.86 
 
N/A N/A N/A 
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CBN Area 270nm   Area 228nm   
Concentrations 1 2 AVG Std Dev RSD% 1 2 AVG Std Dev RSD% 
0.003 3.92 5.17 4.545 0.625 13.75138 
  
N/A N/A N/A 
0.006 7.39 10.87 9.13 1.74 19.05805 43.22 
 
N/A N/A N/A 
0.012 14.57 20.9 17.735 3.165 17.84607 55.7 79.83 67.765 12.065 17.80418 
0.024 29 42.61 35.805 6.805 19.00573 112.7 164.05 138.375 25.675 18.55465 
0.036 43.4 63.19 53.295 9.895 18.56647 170.21 244.38 207.295 37.085 17.88996 
0.048 58.68 84.71 71.695 13.015 18.15329 225.83 329.31 277.57 51.74 18.64034 
0.06 72.03 106.16 89.095 17.065 19.15371 281.31 413.57 347.44 66.13 19.0335 
0.09 109.95 159.35 134.65 24.7 18.34385 427.36 623.11 525.235 97.875 18.63452 
0.12 145.45 
 
N/A N/A N/A 563.43 
 
N/A N/A N/A 
 
Δ9THC Area 270nm   Area 228nm   
Concentrations 1 2 AVG Std Dev RSD% 1 2 AVG Std Dev RSD% 
0.003 0.45 0.69 0.57 0.12 21.05263 
  
N/A N/A N/A 
0.006 0.89 1.37 1.13 0.24 21.23894 28.23 
 
N/A N/A N/A 
0.012 1.75 2.7 2.225 0.475 21.34831 32.55 48.08 40.315 7.765 19.26082 
0.024 3.41 5.51 4.46 1.05 23.5426 66.28 102.05 84.165 17.885 21.24993 
0.036 5.07 7.89 6.48 1.41 21.75926 99.79 144.51 122.15 22.36 18.30536 
0.048 6.82 10.46 8.64 1.82 21.06481 134.38 195.8 165.09 30.71 18.60197 
0.06 8.45 13.7 11.075 2.625 23.70203 167.6 245.02 206.31 38.71 18.76303 
0.09 12.92 20 16.46 3.54 21.50668 255.59 368.02 311.805 56.215 18.0289 
0.12 17.11 
 
N/A N/A N/A 337.45 
 
N/A N/A N/A 
 
Δ8THC Area 270nm   Area 228nm   
Concentrations 1 2 AVG Std Dev RSD% 1 2 AVG Std Dev RSD% 
0.003 0.49 0.71 0.6 0.11 18.33333 
  
N/A N/A N/A 
0.006 0.97 1.46 1.215 0.245 20.16461 
  
N/A N/A N/A 
0.012 1.82 2.68 2.25 0.43 19.11111 26.62 
 
N/A N/A N/A 
0.024 3.65 5.34 4.495 0.845 18.79867 50.91 78.51 64.71 13.8 21.32592 
0.036 5.42 7.89 6.655 1.235 18.55748 77.08 111.53 94.305 17.225 18.2652 
0.048 7.38 10.34 8.86 1.48 16.70429 105.71 151.26 128.485 22.775 17.7258 
0.06 9.07 13.23 11.15 2.08 18.65471 130.26 189.67 159.965 29.705 18.56969 
0.09 13.79 19.76 16.775 2.985 17.79434 198.7 283.1 240.9 42.2 17.51764 
0.12 17.94 
 
N/A N/A N/A 253.56 
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CBC Area 270nm   Area 228nm   
Concentrations 1 2 AVG Std Dev RSD% 1 2 AVG Std Dev RSD% 
0.003 2.65 4.94 3.795 1.145 30.17128 
  
N/A N/A N/A 
0.006 4.11 6.22 5.165 1.055 20.42594 
 
36.24 N/A N/A N/A 
0.012 8.22 11.43 9.825 1.605 16.33588 75.65 52.63 64.14 11.51 17.94512 
0.024 16.84 23.36 20.1 3.26 16.21891 162.2 109.05 135.625 26.575 19.59447 
0.036 24.71 34.77 29.74 5.03 16.91325 235.33 166.22 200.775 34.555 17.21081 
0.048 33.07 46.42 39.745 6.675 16.79457 314.53 222.12 268.325 46.205 17.21979 
0.06 41.13 58.13 49.63 8.5 17.12674 396.91 274.36 335.635 61.275 18.25644 
0.09 62.03 87.2 74.615 12.585 16.86658 594.71 417.82 506.265 88.445 17.4701 
0.12 83.05 
 
N/A N/A N/A 
 
543.45 N/A N/A N/A 
 
 
THCA Area 270nm   Area 228nm   
Concentrations 1 2 AVG Std Dev RSD% 1 2 AVG Std Dev RSD% 
0.003 9.95 
 
N/A N/A N/A 20.24 
 
N/A N/A N/A 
0.0075 11.19 14.8 12.995 1.805 13.88996 49.64 
 
N/A N/A N/A 
0.015 21.19 30.06 25.625 4.435 17.30732 60.21 64.94 62.575 2.365 3.779465 
0.03 41.95 58.48 50.215 8.265 16.45923 88.14 123.78 105.96 17.82 16.81767 
0.06 83.69 118.92 101.305 17.615 17.38809 176.55 266.32 221.435 44.885 20.27006 
0.09 125.31 176.78 151.045 25.735 17.03797 271.43 379.53 325.48 54.05 16.60624 
0.12 167.55 236.35 201.95 34.4 17.03392 365.46 514.08 439.77 74.31 16.89747 
0.15 207.89 296.03 251.96 44.07 17.49087 448.51 646.66 547.585 99.075 18.09308 
0.225 318.49 444.63 381.56 63.07 16.52951 697.82 972.31 835.065 137.245 16.43525 
0.3 413.94 
 
N/A N/A N/A 896.52 
 
N/A N/A N/A 
